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ABSTRACT 
Arrestins are cytosolic G protein-coupled receptor (GPCR) binding proteins that 
regulate several facets of GPCR signaling. Once bound to agonist-occupied 
receptors, arrestins recruit elements of the clathrin-dependent endocytic 
machinery, resulting in removal of GPCRs from the plasma membrane.  The fate 
of internalized receptors is determined by the stability of the GPCR-arrestin 
complex, which is itself dictated by several factors, including ligand structure, 
receptor structure, and arrestin post-translational modifications.  We 
hypothesized that information about ligand and receptor structure is encoded in 
the conformation of the intracellular domains of an activated receptor and 
transferred allosterically to receptor-bound arrestin to dictate which of its many 
cellular functions it will perform.  To test this hypothesis we developed a panel of 
arrestin3 intramolecular FlAsH BRET biosensors that allow detection of 
conformational shifts between the arrestin N-terminus and six positions within the 
protein.  Measuring the effect of receptor activation on arrestin conformation 
generates an arrestin3 ‘conformational signature’ in a live cell, real time, multi-
well plate format.  Using a panel of structurally distinct angiotensin type 1A 
receptor (AT1AR) ligands, we show that GPCR-arrestin complex avidity correlates 
directly with the ligand-induced Δ Net BRET of an arrestin3 FlAsH-BRET sensor 
located within the arrestin3 C-terminal globular domain.  We further hypothesized 
that perturbation of arrestin3 post-translational modifications that influence 
complex stability would similarly be reflected by loss of conformational shifts of 
 ix 
arrestin characteristic of stable complex formation.  Ubiquitination of arrestin3 at 
Lysines 11 and 12 is necessary to stabilize complexes with the AT1AR, but not 
the vasopressin type 2 receptors (V2R).  We found that introduction of an 
arrestin3 K11/12R mutation, which changes the AT1AR-arrestin interaction from 
stable to transient, reduced the arrestin3 C-terminal FlAsH-BRET shift produced 
by AT1AR, but not by the V2R, whose trafficking is unaffected by the mutation.  
We further tested the impact of the K11/12R mutation on two previously 
unstudied receptors, the bradykinin type 2 receptor (B2R) and the type 1 
parathyroid hormone receptor (PTH1R).  Mutation resulted in loss arrestin3 
FlAsH-BRET signal induced by B2R, but not PTH1R.  Examination of arrestin 
trafficking by confocal microscopy demonstrated that the K11/12R  mutation 
altered B2R, but not PTH1R, trafficking.  We conclude that activation-induced 
changes in arrestin3 conformation, observable through intramolecular FlAsH-
BRET, reflect the impact of ligand structure and post translational-modification on 
its intracellular functions.  Biophysical probes such as these, which predict the 
function of intracellular signaling proteins upon receptor activation, may have 
application in drug discovery efforts to identify “biased” ligands that tailor GPCR 


























G Protein-Coupled Receptors and Arrestins 
Heptahelical G protein-coupled receptors (GPCRs) function as ligand-
activated guanine nucleotide exchange factors for heterotrimeric G proteins. 
Agonist binding stabilizes the receptor in an “active” conformation wherein it 
catalyzes the exchange of GTP for GDP on heterotrimeric G protein Gα subunits, 
leading to conformational rearrangements between the GTP-bound Gα subunit 
and the Gβγ subunit heterodimer. Once dissociated, Gα-GTP and Gβγ subunits 
regulate the activity of enzymatic effectors, such as adenylyl cyclases, 
phospholipase C (PLC) isoforms, and ion channels, generating small molecule 
second messengers that control the activity of enzymes involved in intermediary 
metabolism. Predictably, G protein-mediated signaling is subject to extensive 
negative regulation. Second messengers are rapidly inactivated by cyclic 
nucleotide phosphodiesterases, phosphatidylinositol phosphatases, 
diacylglycerol kinases, and the reuptake and extrusion of cytosolic calcium. G 
protein activity is limited by the intrinsic GTPase activity of Gα subunits and the 
extrinsic action of regulators of G protein signaling (RGS) proteins, which 
function as GTPase-activating proteins to return G proteins to their inactive 
heterotrimeric state (Ross and Wilkie 2000). Receptor-G protein coupling is 
controlled by phosphorylation. Second messenger-dependent protein kinases 
like protein kinase (PK)A and PKC mediate heterologous desensitization, so 
named because it does not require ligand occupancy. Phosphorylation of 
intracellular receptor domains by these kinases is sufficient to impair receptor-G 
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protein coupling without the involvement of accessory proteins (Freedman and 
Lefkowitz 1996). In contrast, homologous desensitization is both sensitive to 
receptor conformation and dependent on the binding of arrestins. G protein-
coupled receptor kinases (GRK)1–7 phosphorylate agonist-occupied receptors 
on serine or threonine residues in the receptor C terminus or the third 
intracellular loop (Stoffel et al. 1997). GRK-phosphorylated receptors recruit 
arrestins, which translocate from the cytosol to the plasma membrane to 
physically interdict receptor-G protein coupling. The two nonvisual arrestins, 
arrestin2 (β-arrestin1) and arrestin3 (β-arrestin2), further diminish signaling by 
acting as adapter proteins that link receptors to the clathrin-dependent endocytic 
machinery (Ferguson 2001). Arrestin-dependent sequestration limits signal 
duration; removes receptors from the cell surface, rendering it less responsive to 
subsequent stimuli; and ultimately determines whether receptors “resensitize” 
and recycle to the cell surface or undergo degradation.  
Although the ability of arrestins to act as ligand-regulated adapter proteins 
was first appreciated in the context of GPCR desensitization and sequestration, it 
was the subsequent discovery that the arrestins bind catalytically active proteins 
and redistribute them from the cytosol to the plasma membrane as they dock 
with GRK-phosphorylated receptors that led to a paradigm shift in GPCR biology 
(Luttrell and Lefkowitz 2002; Luttrell and Gesty-Palmer 2010). The capacity to 
function as ligand-regulated scaffolds enables arrestins to nucleate the formation 
of multiprotein “signalsomes” linking GPCRs to novel non-G protein effectors, 
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among them protein and lipid kinases, phosphatases, phosphodiesterases, 
ubiquitin ligases, and regulators of small G proteins. Arrestin binding, then, does 
not mark the end of GPCR signaling, but the transition from one receptor 
signaling state to another. The concept of “pluridimensional efficacy” (Galandrin 
and Bouvier 2006) that arose from the discovery of arrestin-dependent signaling 
recognizes that GPCRs signal via both G protein and non-G protein effectors that 
in sum comprise the signaling repertoire of these versatile receptors. The further 
demonstration that G protein- and arrestin-mediated signals are not only 
mechanistically independent, but also pharmacologically dissociable (Wei et al. 
2003), raises the prospect of “biased” therapeutics that tailor GPCR signaling to 
elicit desired responses while simultaneously antagonizing maladaptive ones 




Generally, all arrestins consist of two globular domains connected by a relatively 
flexible hinge. The structures of the beta- and visual arrestins have been 
extensively studied by X-ray crystallography, and through these studies, a 
number of conserved and functionally important regions have been observed: the 
N-terminal arm, Motif II, the phosphate sensor, the hinge domain, the gate 
loop/polar core, and the C-terminal arm which contains several protein-protein 
interaction motifs.  Figure 1.1 depicts the topological structure of visual/β-
arrestins based on their crystal structure. 
N-Terminal Arm 
Residues in the N-terminus (V11I12F13 of bovine visual arrestin) are 
involved in stabilizing arrestin conformation, while the nearby residues K14 and 
K15 have been implicated in phosphate binding (Vishnevitskiy et al., 2000).  
Alanine substitution of residues 11-13 permits visual arrestin to bind to light-
activated rhodopsin independent of receptor phosphorylation state, indicating a 
role in stabilizing the inactive conformation. Conversely, substitution of residues 
14 and 15 dramatically impairs visual arrestin binding to phosphorylated light- 
activated rhodopsin, suggesting that the two lysines help direct receptor-attached 
phosphates toward the phosphate sensor and participate in phosphate binding in 
the active state. 
Finger Loop / Motif II 
Motif II is located in the finger loop, the uppermost loop (visual arrestin  
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Figure 1.1  Structural topology of arrestins.  Visual/beta-arrestin topologic 
structural analysis showing the overall tertiary fold of arrestins and the major 
functional and interaction domains. A. Ribbon diagram indicating arrestin 
folding from N- (blue) to C-terminus (red). B. Functional domain diagram 
showing areas of functional importance from X-ray and mutagenesis studies.  
Domains are colored such that red regions are involved in receptor binding, 
green regions are involved in oligomerization, blue are important in arrestin 
activiation, and yellow regions interact with microtubules. Analysis and 





residues 68-79) on the N-terminal side of the hinge domain (Granzin et al., 
1998). Motif II exhibits conformational flexibility that is important for high affinity 
receptor binding (Dinculescu et al., 2002; Vishnivetskiy et al., 2004). In the 
unbound state, motif II makes close contact with the arrestin N- domain, but 
when bound to phosphorylated, light-activated rhodopsin it is extended and 
buried in the rhodopsin-arrestin interface (Hanson et al., 2006a; Sommer, et al., 
2007). The finger loop engages a binding crevice on the surface of the activated 
receptor in much the same manner as the Gαt C-terminus (Szczepek et al., 
2014).  Engaging the receptor stabilizes the finger loop structure in the form of a 
reverse turn. 
Phosphate Sensor 
Because visual and beta-arrestins function by binding phosphorylated 
GPCRs, the structure of the phosphate sensor has been studied extensively. 
Visual arrestin binding to rhodopsin is highly dependent on phosphorylation, 
leading to a rapid dissociation rate when bound to unphosphorylated light-
activated rhodopsin, while β-arrestin binding to GPCRs is less phosphorylation-
dependent, relying on contact with non-phosphorylated receptor elements to add 
stability to the interaction (Vishnivetskiy et al., 2011). The primary site of 
phosphorylated receptor interaction is on the positively charged concave surface 
of the two arrestin β-baskets.  Phosphate binding residues have been localized to 
three segments of visual arrestin, including residues 68-78, 170-182, and 330-
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348 (Mokarzel-Falcon et al., 2008). 
Interestingly, the two β-baskets are not symmetrical and the majority of 
direct receptor affinity appears to lie in the N-terminal basket. The phosphate 
sensor, which is integral to controlling the polar core, is designed to be a charge 
operated trigger, with R175 and other amino acids within the 158-185 region 
driving arrestin activation though propagating structural rearrangements 
(Gurevich and Benovic, 1993; Kieselbach, et al., 1994; Vishnivetskiy et al., 2000; 
Han et al., 2001; Nobles et al., 2011). Mutations that destabilize the polar core by 
disrupting the phosphate sensor, e.g. R169E and R175D/E, or removal of the auto-
inhibitory C- terminus, e.g. D383STOP, generate “consitituively active” arrestins 
that lose the ability to recognize receptor phosphorylation while retaining 
selectivity for the ligand activated receptor conformation (Gurevich and Benovic, 
1997; Kovoor et al., 1999). 
Hinge Domain 
The arrestin hinge domain is formed by the conjunction of N- and C-
terminal loops from each half of the protein that come together to create an area 
of regulated flexibility. The hinge region is defined primarily as the loops from 
motif I and IV (Vishnivetskiy et al., 2002). The entire mid-section of the arrestin 
molecule, which contains the polar core and the hinge, is composed of three 
loops from the N-terminal half and two loops from the C-terminal half of the upper 
surface, along with a series of crossing peptide sequences from the bottom face 
of the protein. This interface between the N and C domain is involved in 
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interactions with the arrestin N-terminal helix, GPCR domains, and microtubules. 
Gate Loop and Polar Core 
The polar core is essential to the activation of arrestin. In visual arrestin, 
rearrangement of the polar core is controlled primarily by the gate loop (D296-
N305), also known as the lariat loop (residues 282–309; Han et al., 2001; Kim et 
al., 2013). The gate loop is so named because of its ability to stabilize the polar 
core using charge pair atoms from aspartic acid that interact with arginine in the 
polar core.  The arrestin C-terminus (residues 384-391) interacts with both the N-
terminus and areas on the C-terminal side of the hinge domain, stabilizing the 
inactive arrestin molecule to prevent structural rearrangements and blocking 
effector and specific hydrophobic binding sites (Gurevich and Benovic, 1993). 
Receptor binding displaces the arrestin C- terminus, destabilizing the core and 
exposing new receptor interaction sites (Kim et al., 2013). A salient difference 
between visual arrestin and the non-visual β- arrestins is that the interdomain 
hydrogen-bonds that stabilize the polar core are weakened in β-arrestins, such 
that the hydrogen bond networks in β-arrestin1 and 2 resemble that seen in the 
crystal structure of a ‘pre-activated’ p44 form of arrestin1 (Granzin et al., 2012; 
Kim at al., 2013). This suggests the non-visual arrestins may exist in a partially 
pre-activated state, accounting for their lower dependence upon receptor 
phosphorylation compared to visual arrestin (Gurevich et al., 1995). 
C-terminal Arm 
 The major role of the arrestin C-terminal arm is to work with the gate loop 
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to stabilize the inactive or closed confirmation of arrestin (Shukla et al., 2013). In 
the non-visual arrestins, the C-terminus contains clathrin and AP-2 binding motifs 
that are essential for supporting GPCR endocytosis. Residues 89-100 of the 
clathrin heavy chain bind C-terminal residues 373-377 in β-arrestin2, which 
comprise a conserved LIEFE/LD motif shared by the β-arrestins (Goodman et al., 
1996; Krupnick et al., 1997). This same region of β-arrestin2 contains an RxR 
motif that binds the β2-adaptin subunit of the AP-2 complex and promotes GPCR 
clustering in clathrin-coated pits (Laporte et al., 2000; Kim and Benovic, 2002; 




The duality of arrestin function can be illustrated by a simple experiment. 
Overexpression of either β−arrestin1 or 2 in COS-7 cells expressing the 
angiotensin AT1A receptor blunts angiotensin II-stimulated inositol phosphate 
production via the Gq/11-PLCβ effector pathway, due to accelerated uncoupling 
of the heterotrimeric G protein from its receptor. But the same conditions produce 
a paradoxical increase in AT1A receptor-mediated ERK1/2 activation, indicating 
that arrestins enhance coupling to some downstream effectors while impairing 
others (Tohgo et al. 2002). The physical basis of this paradox lies in the ability of 
arrestins to act as GPCR effectors and mediate G protein-independent ERK1/2 
activation. 
Desensitization 
 Desensitization is initiated by GPCR phosphorylation and occurs rapidly. 
The C-terminal domain of GPCRs is phosphorylated at serine and threonine 
residues in the cytoplasmic loops by cAMP-dependent protein kinase (PKA) and 
protein kinase C (PKC).  These phosphorylation events are sufficient for GPCR 
desensitization, even in the absence of arrestins (Benovic et al 1985).  
Furthermore, agonist occupancy of the receptor is not necessary for this 
phenomenon to occur.  Any stimulus that activates PKA and/or PKC to sufficient 
levels is able to mediate this form of desensitization, and thusly it is referred to as 
heterologous desensitization (Lefkowitz et al 1993).  
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 In contrast, GPCR activation leading to GRK-mediated phosphorylation of 
ligand-bound receptors is referred to as homologous desensitization.  There are 
seven known GRK isoforms, two of which (GRK1 and GRK7) are expressed in 
cone cells of the retina (Weiss et al 1998) and the remaining five (GRK2-6) are 
more widely expressed.  While GRKs also phosphorylate serines and threonines 
in the second and third cytoplasmic loops of GPCRs, GRKs strongly favor 
phosphorylation of ligand-bound receptors.  Additionally, unlike heterologous 
desensitization, termination of heterotrimeric G protein activation is strongly 
dependent on the presence of arrestin (Lohse et al 1993). 
Trafficking 
GPCR endocytosis and trafficking occurs on a slower timeframe than 
desensitization.  GRK-mediated GPCR phosphorylation and binding of arrestin to 
receptors facilitate endocytosis through the recruitment of clathrin and its adapter 
protein AP-2.  Binding motifs on the beta-arrestins exist for each of the binding 
partners.  Clathrin binding is mediated through an LIEF motif on residues 344-
347 of β-arrestin 2 (Krupnick et al 1997).  Clathrin binds β-arrestins in a 
stoichiometric fashion (Goodman et al 1996).  The beta2-adaptin subunit of the 
AP-2 complex binds beta-arrestin 2 at an RxR sequence on residues 394-396 
(Laporte et al 1999; Laporte et al 2000).  Interaction with these binding partners 
leads to trafficking of GPCR-arrestin complexes to clathrin-coated pits and, 
depending on the receptor subtype in question, internalization and partitioning 
into early and late endosomes. 
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Signaling 
In contrast to the clathrin and AP-2 binding sites in the C terminus of β-
arrestins 1 and 2, the binding sites for ERK1/2 cascade components on arrestins 
have not been precisely mapped. Indeed, most data suggest that c-Raf1, 
MEK1/2, and ERK1/2 make multiple contacts with the exposed cytosolic face of 
the receptor-bound arrestin, a feature that may underlie its ability to catalyze 
receptor-dependent ERK1/2 activation (Song et al. 2009). The initial 
observations, based on co-immunoprecipitation from cells transfected with 
pathway components, were that while all ERK1/2 pathway kinases interacted 
with arrestin3, binding of MEK1 and ERK2 was enhanced by co-expressed c-
Raf1, suggesting a cooperative binding interaction. Moreover, activation of 
angiotensin AT1A receptors increased c-Raf1 and ERK2 binding to β-arrestin2, 
and the association of all three proteins with the receptor, consistent with ligand-
dependent complex assembly (Luttrell et al. 2001). Subsequent work 
demonstrated that c-Raf1, MEK1, and ERK2 each bound to the separately 
expressed N- and C domains of all four arrestin isoforms, suggesting that the 
binding sites for all three kinases are bipartite and that binding per se is not the 
key to arrestin-mediated pathway activation (Song et al. 2009). Using 
conformationally biased arrestin mutants that mimic the free, receptor-bound, 
and microtubule-associated conformations of arrestins, it has been possible to 
show that ERK1/2 interacts with high affinity only with the receptor-bound and 
microtubule-associated conformations and exhibits virtually no binding to free 
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cytosolic arrestin (Coffa et al. 2011a). Like ERK1/2, c-Raf1 prefers the receptor-
bound conformation, although the difference is less dramatic, while MEK1 binds 
equivalently to both free arrestin (Meng et al. 2009; Coffa et al. 2011b) and all 
three mutationally constrained conformations (Coffa et al. 2011a). Perhaps 
significantly, cRaf1 and ERK1/2 binding to the microtubule-bound pool of arrestin 
may provide a mechanism for dampening basal ERK1/2 activity in the absence of 
receptor stimulation. In cells, overexpressed visual arrestin, β-arrestin2, and β-
arrestin3, but not arrestin4, recruit ERK1/2 to microtubules and quench its activity 
(Hanson et al. 2007), as does the β-arrestin2 mutant that mimics the microtubule-
associated conformation (Coffa et al. 2011a). On the other hand, arrestin-
dependent activation of ERK1/2 appears to be dependent upon binding to 
GPCRs (Coffa et al. 2011a, b), as originally proposed (Luttrell et al. 2001). 
     Visual arrestin, β-arrestin2, and β-arrestin3 also bind Src family non-
receptor tyrosine kinases and recruit them to activated GPCRs. As with the 
components of the ERK1/2 cascade, the Src binding sites on arrestins have not 
been mapped precisely and appear to involve multiple points of contact. From 
co-immunoprecipitation studies, c-Src appears to interact primarily with the N-
terminal domain of β-arrestin1 (Luttrell et al. 1999), which is proline rich and 
contains three potential SH3 domain-binding Pro-X-X-Pro motifs. A mutated β-
arrestin1, [Pro91Gly–Pro121Glu]-arrestin2, in which two of the three Pro-X-X-Pro 
motifs are disrupted, exhibits impaired c-Src binding and functions as a dominant 
negative inhibitor of β2 adrenergic receptor-mediated ERK1/2 activation. In vitro, 
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β-arrestin1 binds directly to c-Src SH3, but not SH2, domain glutathione S-
transferase fusion proteins. However, the c-Src SH1 domain also contributes to 
arrestin2 binding, since its deletion markedly reduces c-Src binding to full-length 
arrestin2, while the isolated c-Src SH1 domain retains strong binding even 
without the SH2 and SH3 domains (Miller et al. 2001). The β-arrestin1-Src SH1 
domain interaction is independent of kinase activity, since catalytically inactive 
Lys298Met mutants of both full-length c-Src and the isolated SH1 domain retain 
strong β-arrestin1 binding (Luttrell et al. 1999; Miller et al. 2000). Visual arrestin 
also binds c-Src, but the interaction is different. Photobleaching of rod outer 
segments leads to association of active c-Src and visual arrestin with rhodopsin 
(Ghalayini et al. 2002). Visual arrestin has only a single Pro-X-X-Pro motif in the 
N-terminal domain, and bleached rhodopsin and visual arrestin interact with c-
Src SH2 domain and SH2-SH3 domain glutathione S-transferase proteins 
equivalently, suggesting that in this case the c-Src SH2 domain mediates the 
interaction. Unlike the components of the ERK1/2 cascade (see Section 2.2), the 
affinity of c-Src for mutationally stabilized free, receptor- and microtubule-bound 
conformations of arrestins has not been determined. Co-immunoprecipitation 
studies using β2 adrenergic receptors suggest that both the association of c-Src 
with β-arrestin1 and the arrestin-dependent recruitment of c-Src to the receptor 
are agonist dependent (Luttrell et al. 1999). Similarly, the neurokinin NK1 
receptor forms a receptor-β-arrestin1-Src complex in response to substance P 
stimulation (DeFea et al. 2000b). Gel filtration of NK1 receptor complexes from 
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stimulated cells reveals a larger than-expected complex size of ~300 kDa, 
suggesting the ligand-dependent assembly of NK1 receptor-β-arrestin1-Src 
complex containing additional proteins. Although the c-Src associated with 
bleached rhodopsin-bound visual arrestin and β2 adrenergic receptor-bound β-
arrestin1 is Tyr530 dephosphorylated, and therefore presumably active, c-Src 
activation is not a prerequisite for arrestin binding, since both catalytically inactive 
Lys298Met and constitutively active Tyr530Phe mutants of c-Src bind equivalently 
(Ghalayini et al. 2002; Luttrell et al. 1999). Nor is internalization of the receptor-
arrestin complex required for Src binding, since isoproterenol-stimulated 
recruitment of active c-Src to β2 adrenergic receptor-arrestin complexes at the 
plasma membrane can be observed following antibody cross-linking of receptors, 
which causes them to be retained at the cell surface (Luttrell et al. 1999). On the 
other hand, the c-Src binding to β-arrestin1 may be regulated by β-arrestin1 
Ser412 phosphorylation, since a non-phosphorylatable Ser412Ala mutant of β-
arrestin1 retains wild-type binding to c-Src, while a phospho-mimetic Ser412Asp 
mutant is impaired (Luttrell et al. 1999). Ligand-induced dephosphorylation of 
Ser412, which occurs upon β-arrestin1 binding to the β2 adrenergic receptor, may 
thus provide a mechanism for regulating complex assembly (Lin et al. 2002). 
  
 17 
Rationale and Hypothesis 
The β-arrestins bind an enormous variety of GPCRs, and the functions 
they perform are dictated by the activating partner. Even within a single receptor 
system, other factors, such as the ligand that is used or post-translational 
modifications to arrestins, can cause alterations in arrestin’s functionality. It has 
yet to be fully described how arrestin is able to mediate its actions based on the 
precise conditions of its activation. We hypothesized that upon engagement with 
an activated GPCR and subsequent formation of a signalsome, arrestins 
undergo distinct conformational shifts that are reflective of its ensuing function. 
To this end, we examined three specific topics. First, in Chapter 2, we examine 
the necessity of arrestin engagement with an activated receptor for activation of 
arrestin-mediated signals. In parallel with these studies, we examined how G 
protein-mediated signals in the same system were amplified. Second, in Chapter 
3, we outline a novel method β-arrestin2 conformational profiling and 
demonstrate optimization of the system.  Finally, in Chapter 4, we utilize the 
β-arrestin2 conformational profiling technology to examine change in β-arrestin2 
conformational profiles to different factors including activating GPCR subtype, 





























Binding of a ligand to a GPCR elicits a conformational change in the 
receptor that facilitates the recruitment and activation of heterotrimeric G 
proteins. Inactive heterotrimeric G proteins consist of a guanosine diphosphate 
(GDP)-bound alpha subunit in complex with a beta/gamma subunit. A ligand-
bound GPCR serves as a guanine nucleotide exchange factor (GEF) for the 
alpha subunit of the heterotrimeric G protein. Exchange of GDP for guanosine 
triphosphate (GTP) results in the activation of alpha subunit and dissociation 
of the alpha subunit and the beta/gamma subunit. Both the GTP-bound alpha 
subunit and the beta/gamma subunit activate a variety of cellular effectors 
(Lambright et al 1994; Mixon et al 1995).  The effectors activated vary 
depending on the G protein alpha subunit subtype.  One family of effectors 
activated are the GPCR kinases (GRKs). GRKs phosphorylate the intracellular 
loop domains and the cytoplasmic tail of ligand-bound receptors serving two 
roles in termination of GPCR activity: (1) phosphorylated receptors are 
sterically inhibited from further association with heterotrimeric G proteins and 
therefore GEF activity and (2) receptor phosphorylation permits recruitment of 
beta-arrestin (Huang and Tesmer 2011). Receptor-bound beta-arrestin 
functions in GPCR desensitization and trafficking and mediates a 
heterotrimeric G protein-independent activation of cellular effectors. Receptor-
bound beta-arrestin recruits components of the endocytotic machinery such as 
clathrin (Goodman et al 1996) and the AP2 adaptor complex (Laporte et al 
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1999) resulting in the receptor internalization. Activated beta-arrestin also 
serves as a scaffold for a number of signaling complexes including but not 
limited to mitogen-activated protein (MAP) kinases and Src-family non-
receptor tyrosine kinases (nRTKs) (Peterson and Luttrell 2017). Depending on 
the GPCR subtype, the GPCR/beta-arrestin interaction is either transient 
(resulting in recycling of the inactivated receptor to the cell membrane) or 
stable (resulting in prolonged internalization of the receptor and prolonged 
arrestin-mediated signaling). Variations in the nature of the GPCR/beta-
arrestin complex and more in-depth discussion of beta-arrestin’s functions can 
be found in Chapter 1. 
GPCRs are an extremely diverse family of cell surface receptors. All 
GPCRs consist of an amino-terminal extracellular domain, seven 
transmembrane domains connected by intra- and extracellular loop domains, 
and a carboxy-terminal cytoplasmic tail (of widely varying length depending on 
the GPCR subtype). While the proximal step of ligand binding to receptor are 
varied based on the GPCR subtype, the receptor conformational changes that 
lead to heterotrimeric G protein activation show considerable conservation 
(Manglik and Kruse 2017). 
GPCR ligands vary widely in terms of structure and the location of their 
mode of interaction with the receptor.  Ligands can range in size from small 
molecules (such as the catecholamines epinephrine, norepinephrine, and 
dopamine) to large glycoprotein multimers (e.g. the 35.5 kD follicle-stimulating 
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hormone heterodimer). Depending on the receptor subtype, the ligand-binding 
pocket can be formed by the amino-terminal extracellular domain, the 
extracellular transmembrane loops, elements of the transmembrane domain 
bundle, or a combination thereof. Despite these differences, the receptor 
conformational changes that occur between ligand binding and initiation of the 
receptors’ GEF activity are largely conserved. Such similarities include the 
movement of transmembrane (TM) domains and the site of heterotrimeric G 
protein binding to the cytosolic face ligand-bound receptors. Crystallographic 
studies of the photoreceptor rhodopsin (Palczewski et al 2000), fluorescent 
probe- and zinc crosslinking-based studies of beta2- adrenergic receptors 
(Sheikh et al 1996), and cysteine crosslinking studies of M2 muscarinic 
receptors all provide evidence of the importance of movement of sixth TM 
domain in receptor activation. The heterotrimeric G protein binding site is a 
highly conserved sequence on the second and third intracellular loop domains 
(Mirzadegan et al, 2003). 
Heterotrimeric G protein-mediated signaling is a highly amplified process 
(Arshavsky et al, 2002). Activation of adenylyl cyclases by the Gs alpha subtype 
of heterotrimeric G proteins resulting in enzymatic generation of the second 
messenger cyclic adenosine monophosphate (cAMP) serves as a model of this 
signal amplification.  Ligand-mediated GEF activity on heterotrimeric G proteins 
does not require the receptor and heterotrimeric G protein to remain in complex, 
so the activated GTP-bound Gs alpha subunit is free to move about the cell while 
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maintaining its activity. GTP-bound Gs alpha complexes with, and activates, the 
enzyme adenylyl cyclase (AC). AC enzymatically converts ATP to cAMP.  In this 
example, there are multiple potential points of signal amplification, including an 
activated GPCR promoting GTP exchange in several heterotrimeric G proteins 
and a single AC molecule facilitating the conversation of a great number of ATP 
molecules to cAMP. 
In contrast to the apparent amplification of heterotrimeric G protein- 
mediated signaling events, beta-arrestin-mediated signaling is generally 
believed to be unamplified. Evidence for this comes from the observation that 
beta- arrestin’s activity as a scaffold is dependent on being in complex with an 
activated GPCR.  A study of arrestin-mediated activation of the MAP kinase 
pathway downstream of angiotensin type 1A receptor (AT1AR) serves as a prime 
example. While beta-arrestin association with MAP/ERK kinases 1 and 2 
(MEK1/2), or MAP kinase kinase, is not affected by beta-arrestin binding to 
activated AT1AR, both cytoplasmic Raf1 (c-Raf1) and ERK1/2 (the MAP kinase 
kinase kinase and MAP kinase, respectively) was increased by angiotensin II- 
mediated stimulation of AT1AR and the resulting formation of AT1AR/beta-arrestin 
complexes. As the assembly of the MAP kinase signaling components requires 
beta-arrestin to be in complex with an activated receptor, activation of beta- 
arrestin’s downstream effectors is thought to reflect a stoichiometric relation with 
activated GPCRs (Strungs and Luttrell 2014). 
Bioluminescence resonance energy transfer 
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Bioluminescence resonance energy transfer (BRET) is a phenomenon 
that can be exploited as a tool to study protein-protein interactions. BRET 
occurs when the activation of the bioluminescent luciferase substrate occurs in 
sufficient proximity (typically thought to be on the order of 10 Angstroms) to a 
fluorescent donor that the light emitted by the active luciferase substrate can 
activate the fluorescent protein or domain such that a second distinct 
wavelength of light is emitted. The ratio of the intensities of the two wavelengths 
of light emitted (the luminescence of the activated luciferase substrate and the 
fluorescence of the acceptor protein/domain) is a relative measurement of the 
proximity of the fluorescent donor and acceptor.  Changes in this ratio in 
response to stimulation reflect changes in proximity of the donor and the 
acceptor, with an increase in BRET ratio interpreted as the donor and acceptor 
moving closer to each other and vice versa. In this chapter, the donor and 
acceptor are appended to two separate proteins, in which case the 
phenomenon is known as intermolecular BRET (Pfegler et al 2006).  Chapters 
3 and 4 focus beta-arrestin biosensors that have both donor and acceptor 
appended to the same protein for a technique known as intramolecular BRET. 
Two fluorescence donor/acceptor pairs are utilized in this chapter: (1) a BRET1 
pairing of Renilla luciferase (RLuc)-tagged beta-arrestin2 donor and a yellow 
fluorescent protein (YFP)-tagged parathyroid hormone type 1 receptor (PTH1R) 
acceptor; and, (2) and a BRET2 pairing of RLuc2-tagged Gs alpha subunit 
donor and a green fluorescent protein 10 (GFP10)-tagged G beta/gamma 
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subunit acceptor. These BRET pairs were utilized to examine recruitment of 
beta-arrestin to activated PTH1Rs and activation of Gs alpha in response to 
PTH1R stimulation respectively. 
Measurement of cAMP by the cAMP GloSensor assay 
The cAMP GloSensor assay is a luciferase-based assay that allows for 
the measurement of cAMP accumulation. As cAMP is produced, it binds a 
modified luciferase biosensor, resulting in a conformational shift and activation 
of the biosensor. The activated biosensor is able to enzymatically convert a 
coelentrazine-based substrate to a light-emitting active state, and the measure 
luminescence reflects the relative concentration of cAMP in the cells as a result 
of stimulation.  Activated Gs alpha activates AC to promote production of cAMP 
as described above, so this technique was used to determine the extent of 
effector activation downstream of heterotrimeric G protein activation (Binkowski 
et al, 2011). 
Hypothesis 
Based on previous studies of signal amplification downstream of GPCR 
activation, we hypothesized that Gs alpha-mediated signals downstream of 
PTH1R activation would exhibit considerable amplification while arrestin- 
mediated signaling would be essentially stoichiometric. Furthermore, we 
hypothesized that amplification of the Gs alpha-mediated signaling would both 
occur at the level of heterotrimeric G protein activation by ligand-bound 
receptors and the AC-mediated enzymatic production og cAMP. To this end, we 
 25 
examined and compared efficacy of PTH1R ligand PTH[1-34] in inducing 
changes at various levels of signaling, including: heterotrimeric G protein 
activation, beta-arrestin2 recruitment, accumulation of second messenger 




Parathyroid hormone [1-34] (PTH[1-34]) was suspended in sterile, 
deionized water at a concentration of 1 mM, aliquoted, and stored at -20º C 
until day of use. 
Coelenterazine for BRET1 was suspended in a solution of 10 mL 
absolute ethanol and 200 µL 5N HCl, aliquoted, and stored at -80º C until day 
of use. Deep blue coelenterazine for BRET2 (DeepBlueC) was suspended in 
10 mL absolute ethanol and 200 µL 5N HCl, aliquoted, and stored at -80º C 
until day of use. 
GloSensor™ cAMP reagent was suspended in 8.17 mL of HEPES 
buffer (10 mM in deionized water, pH 7.5), which was then aliquoted and 
stored at -80º C until day of use. 
Tissue culture 
For PTH1R-YFP/RLuc-beta-arrestin2 BRET1 and Gs alpha-RLuc/G 
beta/gamma- GFP10 BRET2 experiments, human embryonic kidney 293 
(HEK293) cells were used. Cells were grown in growth medium consisting of 
minimum essential medium (MEM) containing 10% fetal bovine serum (FBS), 2 
mM L- glutamine, and antibiotic/antimycotic. HEK293 cells were maintained in 10 
cm2 plastic cell culture dishes and grown in an incubator maintained at 37º C and 
5% CO2.  Cells were passaged at 90% confluency.  HEK293 cells were used for 
experiments on passages two through eight (P2-P8). 
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For GloSensor™ cAMP experiments, HEK293 cells stably expressing the 
GloSensor™ cAMP biosensor were used. Cells were grown in growth medium 
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% FBS, 
2 mM L-glutamine, antibiotic/antimycotic, and 5 µg/mL hygromycin B for 
selection. GloSensor™ cAMP-expressing HEK293 cells were maintained in 10 
cm2 plastic cell culture dishes and grown in an incubator maintained at 37º C and 
5% CO2. Cells were passaged at 90% confluency and used for experiments on 
P2-P8.  
For ERK activation studies, Flp-In HEK293 cells with a stably transfected, 
tetracycline-inducible beta-arrestin 1 and 2 short hairpin RNA (shRNA) were 
used.  Addition of 1 µg/mL of doxycycline for 24 hours prior to the experiment 
induces the expression of beta-arrestin 1 and 2 targeting shRNA that results in 
an almost complete knockdown of beta-arrestin 1 and 2.  Flp-In HEK293 cells 
were grown in growth medium consisting of MEM containing 10% FBS, 2 mM L-
glutamine, antibiotic/antimycotic, and 10 µg/mL blasticidin and 10 ug/mL 
hygromycin B for selection maintenance.  Flp-In HEK293 cells were maintained 
in 10 cm2 plastic cell culture dishes and grown in an incubator maintained at 37º 
C and 5% CO2. Cells were passaged at 90% confluency and used for 
experiments on P2-P8. 
GPCR-arrestin intermolecular BRET 
On day one of the experiment, HEK293 cells were seeded onto 6-well 
plastic culture dishes such that they would be at approximately 40-50% 
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confluence the following day. Each well was grown with 2 mL of complete MEM 
growth medium. 
On day two, cells were transfected with FuGENE HD using an adapted 
version of the recommended protocol.  For each transfection reaction, 94 µL of 
plain MEM was combined with 6 µL of FuGENE HD in a plastic microfuge tube, 
gently vortexed, spun for approximately 5 seconds at 10,000 x g, and allowed to 
incubate for five minutes at room temperature. After five minutes, plasmid DNA 
was added to each transfection reaction. For each reaction, 1.5 µg of PTH1R-
YFP cDNA and 200 ng of RLuc-beta-arrestin2 cDNA were added.  Microfuge 
tubes were inverted several times to facilitate mixing, spun for approximately 5 
seconds at 10,000 x g, and allowed to incubate for ten minutes at room 
temperature. After this incubation, the entire contents of each transfection 
reaction was added to the appropriate well, and the plate was returned to the 
incubator. 
On day 3, the growth medium containing the transfection reaction 
was aspired from the cells and replaced with complete MEM growth 
medium. 
On day 4, the BRET experiment was performed. Growth medium was 
aspired from the cells and replaced with phosphate-buffered saline (PBS) 
containing 2 mM EDTA to detach the cells from the plate. Gentle pipetting with a 
micropipettor was used to aid cell detachment. Once cells were detached, the 
suspended cells were pipetted into a plastic microfuge tube. Tubes were spun in 
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a microfuge at 3,000 x g for three minutes. The supernatant was carefully 
aspirated, leaving the cell pellet undisturbed. To each tube, 650 µL of BRET 
buffer containing 1 mM CaCl2, 140 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 0.36 
mM NaH2PO4, 5.5 mM d-glucose, 12 mM NaHCO3, 25 mM HEPES, pH 7.4 was 
added and cells were gently pipetted up and down several times to suspend the 
cells.  The cell suspension was transferred to the assay plate, a 96-well opaque 
white plastic plate, with 100 µL of cell suspension per well. The assay plate was 
wrapped in aluminum foil during transfer and until the assay was ready to be 
run. PTH[1-34] for stimulation of the cells was prepared at 12X working 
concentration in BRET buffer.  For this experiment, a dose-response curve was 
generated using concentrations ranging from 3 nM to 10 µM at half-log intervals. 
BRET experiments were run on a Tristar 3 LB 941 Multi-mode Microplate 
Reader (Berthold Technologies).  Transfection efficiency was verified by 
measuring YFP fluorescence at wavelength of 530 nm.  After confirmation of 
construct expression by YFP fluorescence, 10 µL of varying PTH[1-34] 
concentrations or vehicle consisting of BRET buffer were added to each well 
using a multichannel micropipettor. Drug mixing was ensured by pipetting up 
and down gently several times. Each drug concentration was tested in triplicate 
each experiment, and values were averaged. Immediately after adding PTH[1-
34] to the assay plate, coelenterazine was prepared by adding 25 µL of stock 
solution to 1 mL of BRET buffer. After thorough vortexing, 10 µL of diluted 
coelenterazine was added to each well. The assay plate was put in the 
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instrument and emission at the wavelength ranges of 458 nm and 530 nm were 
measured for coelenterazine luminescence and YFP respectively. The BRET 
ratio was measured as the luciferase value divided by the YFP value. Changes 
in BRET were measured as the difference of the vehicle-treated control and the 
PTH[1-34]-stimulated values. Analysis of data was performed in GraphPad 
Prism. 
BRET2 assay of heterotrimeric G protein rearrangement  
On day one of the experiment, HEK293 cells were seeded onto 6-well 
plastic culture dishes such that they would be at approximately 40-50% 
confluence the following day. Each well was grown with 2 mL of complete MEM 
growth medium. 
On day two, cells were transfected with FuGENE HD using an adapted 
version of the recommended protocol. For each transfection reaction, 94 µL of 
plain MEM was combined with 6 µL of FuGENE HD in a plastic microfuge tube, 
gently vortexed, spun for approximately 5 seconds at 10,000 x g, and allowed to 
incubate for five minutes at room temperature. After five minutes, plasmid DNA 
was added to each transfection reaction. For each reaction, 1.2 µg of PTH1R 
cDNA, 100 ng of RLuc-Gs alpha cDNA, and 400 ng of GFP10-tagged G beta- 
gamma were added. Microfuge tubes were inverted several times to facilitate 
mixing, spun for approximately 5 seconds at 10,000 x g, and allowed to 
incubate for ten minutes at room temperature. After this incubation, the entire 
contents of each transfection reaction was added to the appropriate well, and 
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the plate was returned to the incubator. 
On day 3, the growth medium containing the transfection reaction 
was aspired from the cells and replaced with complete MEM growth 
medium. 
On day 4, the BRET experiment was performed. Growth medium was 
aspired from the cells and replaced with phosphate-buffered saline (PBS) 
containing 2 mM EDTA to detach the cells from the plate. Gentle pipetting with a 
micropipettor was used to aid cell detachment.  Once cells were detached, the 
suspended cells were pipetted into a plastic microfuge tube.  Tubes were spun 
in a microfuge at 3,000 x g for three minutes. The supernatant was carefully 
aspirated, leaving the cell pellet undisturbed. To each tube, 650 µL of BRET 
buffer containing 1 mM CaCl2, 140 mM NaCl, 2.7 mM KCl, 0.9 mM MgCl2, 0.36 
mM NaH2PO4, 5.5 mM d-glucose, 12 mM NaHCO3, 25 mM HEPES, pH 7.4 was 
added and cells were gently pipetted up and down several times to suspend the 
cells. The cell suspension was transferred to the assay plate, a 96-well opaque 
white plastic plate, with 100 µL of cell suspension per well. The assay plate was 
wrapped in aluminum foil during transfer and until the assay was ready to be 
run. PTH[1-34] for stimulation of the cells was prepared at 12X working 
concentration in BRET buffer.  For this experiment, a dose-response curve was 
generated using concentrations ranging from 3 nM to 10 µM at half-log intervals. 
BRET2 experiments were run on a Tristar 3 LB 941 Multi-mode Microplate 
Reader.  10 µL of varying PTH[1-34] concentrations or vehicle consisting of 
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BRET buffer were added to each well using a multichannel micropipettor. Drug 
mixing was ensured by pipetting up and down gently several times. Each drug 
concentration was tested in triplicate each experiment, and values were 
averaged. Immediately after adding PTH[1-34] to the assay plate, DeepBlueC 
was prepared by adding 25 µL of stock solution to 1 mL of BRET buffer. 
DeepBlueC is extremely sensitive to light, so from preparation of DeepBlueC 
from stock solution, through completion of the assay, all steps were performed in 
the dark. After thorough vortexing, 10 µL of diluted DeepBlueC was added to 
each well.  The assay plate was put in the instrument and emission at the 
wavelengths of 400 nm and 510 nm were measured for DeepBlueC 
luminescence and GFP10 respectively.  Again due to DeepBlueC’s instability, 
care was taken to ensure measurements were made immediately following 
DeepBlueC addition to the reaction. The BRET2 ratio was measured as the 
luciferase value divided by the GFP10 value. Changes in BRET2 were measured 
as the difference of the vehicle-treated control and the PTH[1-34]-stimulated 
values.  Analysis of data was performed in GraphPad Prism. 
GloSensor™ cAMP assay 
On day one, HEK293 cells stably expressing the GloSensor™ cAMP 
biosensor were passaged to a 10 cm2 plastic tissue culture dish such that cells 
would be at 30-40% confluency the following day. 
On day two, cells were transfected with untagged PTH1R plasmid cDNA 
using FuGENE HD as a transfection reagent. The transfection protocol was 
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modified from the provided FuGENE HD transfection protocol. In a plastic 
microfuge tube, 570 µL of plain DMEM and 30 µL of FuGENE HD were 
combined, gently vortexed to ensure mixing, and spun for approximately five 
seconds at 10,000 x g. The mixture was incubated for five minutes at room 
temperature. Following incubation, 10 µg of PTH1R plasmid cDNA was added to 
the transfection reaction. The microfuge tube was inverted several times to 
ensure mixing and spun for approximately five seconds at 10,000 x g. The 
transfection reaction was incubated for ten minutes at room temperature.  
Following incubation, the entire contents of the transfection reaction was added 
directly to the appropriate tissue culture plate. 
On morning of day three, the transfected cells were split to clear- 
bottomed, white-walled 96-well assay plates. Assay plates were coated with 
collagen I to prevent cell detachment during the assay. 100 µL of the collagen I 
solution was added to each well and allowed to incubate for one hour at room 
temperature. Following the incubation, the collagen I solution was aspirated and 
each well was washed twice with PBS to remove the excess collagen I solution. 
50 µL of complete DMEM growth medium was added to each well of the assay 
plate. The transfected cells from were detached from the plate using 5% trypsin 
solution, spun at 1,300 x g for three minutes to remove trypsin solution, and 
resuspended in 5 mL of complete DMEM growth medium. 50 µL of the 
resuspended cells were added to each well of the assay plate. 
On the evening of day three, the growth medium as aspirated from 
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each well of the assay plate and replaced with serum starvation medium that 
was identical to the complete DMEM growth medium with the exception that it 
contained 1% FBS instead of 10% FBS. 
On day four, the assay was performed. GloSensor™ cAMP reagent was 
reconstituted according to manufacturer directions, aliquoted in 200 µL 
portions, and stored at -80º C. On the day of the experiment, an aliquot was 
thawed and the GloSensor™ cAMP reagent medium was prepared by adding 
10 mL of DMEM containing 10 mM HEPES (pH 7.4). The medium was 
prewarmed in a water bath. The serum starvation growth medium was gently 
aspirated from the assay and 100 µL of the reagent medium was added to 
each well using a multichannel pipettor. The assay plate was incubated at 37º 
C in the tissue culture incubator for one hour, and then removed from the 
tissue culture incubator and incubated for an addition 30 minute at room 
temperature in the dark. During the reagent medium incubation period, the 
ligand dosing plate was prepared. PTH[1-34] was diluted from 1 mM stock 
concentrations to 5X working concentrations in 10 mM HEPES-buffered 
DMEM. Each well of a round bottom 96-well drug plate was loaded 40 µL of 5X 
PTH[1-34] for the corresponding well in the assay plate. For this dose-
response experiment, working concentrations ranged from 0.01 nM to 10 µM at 
log intervals. A positive control of 10 µM forskolin, a direct activator of AC, was 
included with each replicate. 
Assay plates were analyzed in a FLIPRTETRA fluorescence imaging plate 
 35 
reader system (Molecular Dynamics, Inc.). In accordance with the GloSensor™ 
cAMP assay relying only on luminescence observations, excitation and emission 
filters are disabled and the emission filter is removed. The assay was conducted 
at room temperature in the FLIPRTETRA. The drug dispensing settings on the 
instrument were set such that 25 µL of 5X PTH[1-34] would be aspirated from 
the drug plate and transferred to the assay plate, bringing the total volume in 
each well to 125 µL and diluting the PTH[1-34] to the final working 
concentration. FLIPRTETRA instrument settings were detection gain of 280,000, 
exposure gain of 0.53 seconds, and the gate open 100%. Baseline 
luminescence was established with one read per second for ten seconds, then 
following drug addition to the assay plate with one read per second for fifty 
seconds. Following that, luminescence was measured once every two seconds 
for 600 reads. Altogether, 660 luminescence measurements were observed over 
21 minutes for each well. Data were analyzed in Microsoft Excel. 
G protein-dependent and –independent components of ERK activation 
On day one, Flp-In HEK293 stably transfected with inducible beta-
arrestin 1 and 2 shRNA were split to 12-well plastic tissue culture dishes such 
that cells would reach 30-40% confluency by the following day. Each well 
contained 1 mL of complete MEM medium containing tetracycline-free FBS and 
100 µg/mL of each hygromycin B and blasiticidin for selective maintenance. 
On day two, all wells were transfected with PTH1R using FuGENE HD 
and a transfection protocol adapted from manufacturer recommendations. For 
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each well, 47 µL of MEM was combined with 3 µL of FuGENE HD in a microfuge 
tube. Tubes were vortexed to ensure mixing and centrifuged at 10,000 x g for 
approximately five seconds. The mixture was incubated at room temperature for 
five minutes. After this incubation, 1 µg of PTH1R plasmid cDNA was added to 
each transfection reaction. Tubes were inverted several times to ensure mixing, 
centrifuged at 10,000 x g for approximately five seconds, and incubated at room 
temperature for ten minutes. Following incubation, the entire contents of the 
transfection reaction was added directly to the well. Later that evening, 
doxycycline was added to half of the wells to a final concentration of 1 µg/mL. 
Doxycycline was prepared fresh each day at a 100X concentration in sterile 
deionized water due to rapid loss of activity once suspended. 
On day three, growth medium containing the transfection reaction was 
aspirated from the wells and replaced with fresh complete MEM medium 
containing selection antibiotics. Additionally, doxycycline was added again to the 
appropriate wells. 
On the morning of day four, the growth medium was aspirated and 
replaced with serum starvation MEM medium containing 0.1% FBS with or 
without doxycycline. Cells were serum starved for approximately four hours to 
diminish relatively levels of basal ERK phosphorylation seen in HEK293 cells. 
Following serum starvation, the assay was performed. For this dose- 
response experiment, a concentration range of 1 nM to 10 µM was used as log 
intervals.  Serial dilution of the 1 mM stock solution of PTH[1-34] was performed 
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at 1000X working concentrations in PBS, and then each dilution condition was 
diluted to the final working concentration in MEM. To stimulate the cells, serum 
starvation MEM medium was gently aspirated and replaced with MEM 
containing either vehicle control or PTH[1-34]. Plates were placed back in the 
tissue culture incubator at 37º C for ten minutes. Following the drug stimulation 
period, plates were removed from the incubator, the drug-containing medium 
was gently aspirated, and plates were placed on ice. 100 µL of 1X SDS sample 
buffer containing whatever was added directly to each well. Each sample was 
pipetted up and down to fully detach all cells from the plate, and samples were 
kept on ice until complete. Each sample was sonicated for ten seconds and then 
centrifuged for five minutes at 10,000 x g.  Following centrifugation, the 
supernatant was transferred to a new microfuge tube and stored -20˚ C until 
ready for Western blot analysis. 
Gel electrophoresis was performed using a Novex Minigel system. Tris-
glycine gels with a variable 5-20% gradient were used. Samples were loaded by 
equal volume and loading was confirmed by total ERK levels. Electrophoresis 
was performed using a voltage of 120 V and gels were run for approximately 
two and a half hours. Transfer to nitrocellulose membranes was performed 
using an iBlot system.  Transfer was performed using these conditions for nine 
minutes. 
Membranes were blocked using 5% milk in TBS-T for one hour on a 
shaker at room temperature. Following blocking, milk was discarded and blots 
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were rinsed with TBS-T to remove excess milk solution. For ERK activation 
studies, blots were incubated with rabbit polyclonal anti-phospho-p44/42 
ERK1/2 (cat no 9101) or anti-ERK1/2 (cat no 9102; Cell Signaling Technology, 
Danvers, MA) at a dilution of 1:2,000 in 5% bovine serum albumin overnight at 
4˚ C. The following day, the primary antibody was removed and the blot was 
washed with TBS-T and vigorous shaking five times for five minutes each. 
Following the last wash, goat anti-rabbit Ig conjugated with horseradish 
peroxidase (HRP) was diluted at a dilution of 1:10,000 and added to each blot. 
The blots were incubated for one hour on the shaker at room temperature. 
Following incubation in the secondary antibody, the antibody solution was 
discarded and the blot was washed in the same manner as previously. Pierce 
West Dura was used as an HRP substrate for detection and prepared according 
to manufacturer guidelines. X-ray films were exposed over the blots in the 
darkroom and processed.  Developed films were scanned and analyzed.  
To discriminate G protein-dependent and  beta-arrestin-dependent 
ERK1/2 activation, measurements made in cells that were not treated with 
doxycycline were interpreted as total ERK activation (G protein + beta-arrestin)  
downstream of PTH1R activation.  Measurements made in cells treated with 
doxycycline were interpreted as G protein-dependent component of signaling. 
The difference between the doxycycline-treated and non-doxycycline-treated 
measurements represented the arrestin-dependent component of ERK 




Heterotrimeric G protein rearrangement by BRET2	
As shown in Figure 2.1, a dose-response curve for was obtained using 
concentrations of PTH[1-34] ranging from 30 nM to 10 µM at half log intervals. 
Heterotrimeric G protein rearrangement was measured by using a BRET2 pair 
of RLuc-Gs alpha and GFP10-tagged G beta-gamma in HEK293 also co-
transfected with PTH1R.  The Vmax of 0.287 was achieved at a dose of 1 µM and 
the EC50 was observed to be a concentration of 237 nM. Due to the high 
instability of the DeepBlueC luciferase substrate, only a single time point was 
observed, approximately two minutes after addition of PTH[1-34].  
Recruitment of β-arrestin 2 to PTH1R is unamplified	
As shown in Figure 2.2, a dose-response curve for was obtained using 
concentrations of PTH[1-34] ranging from 3 nM to 10 µM at half log intervals. 
Beta-arrestin 2 recruitment was determined by intermolecular BRET between a 
RLuc-beta-arrestin2 donor and a PTH1R-YFP acceptor. Measurements were 
made between two and ten minutes for all replicates, and a maximum value 
was obtained at the earliest time point that remained stable until the last time 
point.  The Vmax of 1.01 was achieved at a dose of 300 nM and the EC50 was 
observed to be a concentration of 83 nM. 
cAMP GloSensor Assay 
As shown in Figure 2.3, a dose-response curve for cAMP accumulation in 













Figure 2.1. Heterotrimeric G protein rearrangement in response to PTH[1-34]. 
PTH[1-34] induced a dose-dependent response in heterotrimeric G protein 
rearrangement as observed by RLuc-Gsα/GFP10-Gβ/γ BRET2. PTH[1-34] was 
used in a range of concentration from 30 nM to 10 µM at half-log intervals. An 
EC50 of 237 nM and a Vmax of 0.287 were observed. Each replicate was 
performed in triplicate and N = 5 independent experiments.  Error bars 

















Figure 2.2. Arrestin3 recruitment in response to PTH[1-34]. PTH[1-34] induced 
a dose- dependent response in arrestin3 recruitment as observed by PTH1R-
YFP/RLuc-arr3 BRET. PTH[1-34] was used in a range of concentration from 30 
nM to 10 µM at half-log intervals. An EC50 of 83 nM and a Vmax of 1.01 were 
observed. Each replicate was performed in triplicate and N = 6 independent 















Figure 2.3. PTH[1-34] induces dose-dependent accumulation of cAMP.  cAMP 
accumulation was measured in response to doses of PTH[1-34] ranging from 10 
pM to 10 µM by the cAMP GloSensor™ assay conducted in a FLIPRTETRA 
plate reader. Values are displayed relative to maximum relative light units (RLU) 
observed in each individual experiment. An EC50 of 9.7 nM was observed. 
Each measurement was observed in duplicate and n = 3 independent 




cAMP GloSensor assay where cAMP binds and activates a luciferase-based 
reporter. The assay was run over the course of twenty minutes, and maximum 
values were observed at approximately 5 minutes, and were stable for the 
remainder of the experiment. The Vmax of 0.93 was achieved at a dose of 100 
nM and the EC50 was observed to be a concentration of 9.7 nM.  
shRNA-inducible HEK pERK assay	
Activation of ERK was measured by Western blot in inducible shRNA 
beta-arrestin1/2 HEK293 cells in both the presence and absence of induction of 
shRNA transcription. In the un-induced cell background, i.e. the cells not treated 
with doxycycline, both beta-arrestin 1 and 2 were present at wild type 
expression levels, the activation of ERK represented the total of both G protein-
dependent and –independent components. In doxycycline-induced cells, beta-
arrestin 1 and 2 expression was knocked down. In this cell background, the 
activation of ERK observed by measurement of phospho-ERK represents only 
the G protein-dependent component of signaling as there is almost completel 
downregulation of beta-arrestin 1 and 2 expression.  The G protein-
independent, i.e. the arrestin-dependent, component of signaling was 
determined by subtraction of the G protein-dependent component from the total 
ERK activation. Dose- response curves were generated for each of these 
components, as shown in Figure 2.4. The Km for the total, G protein-dependent, 












Figure 2.4. G protein-dependent and –independent components of ERK 
activation in response to PTH[1-34]. Activation of ERK was measured by 
Western blot of phosphorylated ERK. Doxycycline-inducible βarr1/2 shRNA 
FlpIn HEK293 were stimulated in the presence and absence of doxycycline by a 
range of PTH[1-34] doses from 1 nM to 10 µM. Cells not treated with 
doxycycline express a full complement of arrestins and represent the total ERK 
activation. Cells treated with doxycycline have diminished arrestin expression 
and ERK activation is interpreted as G protein-dependent. The difference of the 
two curves is interpolated as the G protein-independent, or arrestin-dependent, 
component of ERK activation. The EC50 for total, G protein-dependent, and 
arrestin-dependent activation of ERK by PTH[1-34] was observed to be 141 nM, 
1.7 nM, and 369 nM respectively.  N = 4 independent experiments.  Error bars 
represent Mean +/- SEM.  
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DISCUSSION 
The EC50 values for each of the experiments are shown in Table 2.1. The 
dose-response curves for all of the experiments are compared in a relative and 
normalized fashion in Figure 2.5.  Together these demonstrate what was 
expected at the outset: that the downstream signals of G protein-dependent 
signaling were amplified and the downstream signals of arrestin-dependent 
signaling were not amplified. This is indicated by the right shift of the cAMP 
accumulation, itself a direct downstream effect of Gs alpha activation, and the 
doxycycline-induced pERK dose-response curves. The arrestin-dependent ERK 
activation curve determined by subtraction, however, exhibited no shift relative 
to the beta-arrestin 2 recruitment as observed by BRET. This would indicate that 
beta-arrestins are activated in a stoichiometric fashion, and suggests that they 
must be in complex with an activated receptor in order to exert their actions. 
While the most downstream effectors of G protein-mediated signaling 
were shown to amplified, an unexpected observation was that heterotrimeric G 
protein activation was not shifted relative to beta-arrestin 2 recruitment, which 
would seem to indicate that this level of the process is not a level of significant 
amplification. It has been widely thought that an activated GPCR was capable of 
activating a number of heterotrimeric G proteins in concert, but this finding 
suggests that this may not be the case.  Possible explanations for this 
observation may be that complex formation between GPCR and heterotrimeric 




























Figure 2.5. Comparison of relative dose-responses by assay. Dose-response 
curves as observed for each assay were normalized to the maximum response 
observed and plotted together.  Arrestin-dependent activation of ERK shows no 
curve shift relative to its most proximal component, arrestin recruitment to 
activated PTH1R. G protein-dependent activation of ERK and accumulation of 
cAMP are left-shifted relative to heterotrimeric G protein rearrangement, 
however, indicating that amplification of G protein-mediated signals is occurring 




activation by ligand binding to deactivation by arrestin binding may limit the 
number of heterotrimeric G protein activations cycles that are able to be 
completed. While this was an unexpected finding, this result has been repeated 
in unpublished studies by colleagues Hebert and others. 
The classical description of heterotrimeric G protein activation by GPCRs 
is that the alpha and beta/gamma subunits dissociate upon activation. The 
observation of an increase in BRET in response to receptor activation as seen 
in this study would appear to contradict this.  This phenomenon, however, is 
one that has been previously observed in experiments using these or similar 
BRET pairs. In fact, altering the location of the GFP10 acceptor tag between the 
N- and C- termini changes the directionality of the BRET shift. Therefore, a 
more accurate interpretation of heterotrimeric G protein activation is that a 
rearrangement of the alpha and beta/gamma subunits relative to each other is 
occurring rather than a complete dissociation. 
Future directions for these studies focus on use of these same assays for 
different, biased, ligands in a common receptor system. One such ligand of 
particular interest is the bovine PTH analog [D-Trp12,Tyr34]-bPTH[7-34] 
(bPTH(7-34). This ligand has been shown to be able to activate arrestin-
dependent phosphorylation of ERK, but recruitment of beta-arrestin 2 to PTH1R 
has never been reported by any of the common tests of beta-arrestin 2 
recruitment. One possible explanation for these observations is that beta-
arrestin 2 is recruited to PTH1R in these experiments, but that the association is 
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transient and the beta-arrestin 2 dissociates so quickly that current techniques 
are unable to measure it. Although the arrestin has dissociated from the GPCR, 
it is possible that it remains activated for some period of time, resulting in 
arrestin-dependent ERK activation. If repeated recruitment of beta-arrestin 2 to 
the receptor, however tenuous its interaction may be, occurred at a high enough 
rate, this momentary remained of beta-arrestin 2 activity may represent the 

























The arrestins are a family of four cytosolic proteins that play critical roles 
in the modulation of GPCR signaling (Peterson et al 2017).  In particular, the two 
non-visual arrestins, arrestin2 and 3 (also called β-arrestin1 and 2) possess the 
capacity to recognize and bind the agonist-occupied conformation of hundreds of 
different extra-retinal GPCRs.  Arrestin binding promotes homologous 
desensitization and clathrin-dependent sequestration of receptors, while at the 
same time nucleating the assembly of GPCR-arrestin “signalsomes” that can 
generate G protein-independent signals from protein complexes that use the 
GPCR-bound arrestin as a scaffold.  Importantly, the exact functions arrestins 
perform vary depending on the ligand/receptor complex to which they are bound, 
suggesting that information encoded in ligand and receptor structure is 
transferred allosterically to the arrestin in a manner that specifies its function.  
Detecting and classifying these different arrestin “activation modes” requires a 
method for monitoring the conformational changes that occur upon GPCR 
activation in live cells. 
Development of the arrestin FlAsH-BRET biosensors 
BRET is a phenomenon that results from non-radiative energy transfer 
between an enzymatically-activated luminescent substrate donor, e.g. Renilla 
luciferase (Rluc), and a fluorphore acceptor, e.g yellow fluorescent protein (YFP) 
(Pfegler et al 2006).  BRET occurs only when the donor and acceptor are in 
extremely close proximity (<10 nm) and changes in BRET are generally 
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interpreted as movement of the donor and acceptor relative to each other.  When 
the BRET donor and acceptor are appended to separate proteins, e.g. GPCR 
and arrestin, stimulus-induced increases in BRET can be interpreted as protein-
protein interaction (Charest et al 2003).  If, however, the donor and acceptor are 
appended to a single protein, e.g. Rluc-arrestin-YFP, then changes in BRET may 
reflect a number of things, including conformational shifts within the protein that 
change the distance/orientation of donor and acceptor or steric interference 
resulting from recruitment of receptor or non-receptor binding partners (Charest 
et al 2005).   
 Adapting an intramolecular BRET approach to detecting how different 
binding partners, e.g. GCPRs, affect the conformation of a common effector, e.g. 
arrestin, requires being able to measure BRET efficiency between a donor at a 
fixed position and acceptor located at different positions along the protein.  This 
cannot be easily achieved using conventional donor-acceptor pairs, as it would 
require a relatively large acceptor protein to be inserted at several points within 
the target protein, which would almost certainly interfere with its function.  An 
alternative is to employ a small membrane-permeant fluorescein derivative with 
two arsen-(III) substituents (fluorescein arsenical hairpin binder or FlAsH) as the 
acceptor along with an N- or C-terminal Rluc as the BRET donor.  The FlAsH 
acceptor can then be targeted to multiple sites within the protein by mutational 
insertion of a small tetracysteine tag motif (Hoffman et al 2005).  
The six Rluc-arrestin3-FlAsH expression plasmids used in this protocol 
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were constructed by inserting a cDNA sequence encoding the tetra-cysteine 
motif, C-C-P-G-C-C, immediately following amino acid residues 77, 140, 171, 
225, 263, and 410 of rat arrestin3 into the previously described pcDNA3.1-Rluc-
arrestin3 plasmid (Perroy et al 2003).  Insertion sites were chosen based on 
available x-ray crystallographic structures of inactive and GPCR-bound arrestins 
(Han et al 2001; Zhan et al 2011; Shukla et al 2013; Kim et al 2013; Kang et al 
2005) to be away from structural elements likely to be necessary for protein 
folding and stability.  Since arrestin activation results in displacement of the C-
terminus and an approximately 20˚ rotation of the N and C globular domains 
relative to one another (Han et al 2001; Kang et al 2005), the tetra-cysteine 
motifs were placed near the C-terminus and at sites predicted to be on the 
surface of the N and C domains away from known sites of GPCR interaction 
(Figure 3.1) (Lee et al 2016). To determine whether the Rluc-arrestin3-FlAsH1-6 
constructs remained functional, intermolecular BRET between each construct 
and the GPCRs of interest bearing a C-terminal YFP tag was measured following 
well-described protocols (Pfegler et al 2006; Charest et al 2003).  Once the Rluc-
arrestin3-FlAsH constructs were validated, intramolecular FlAsH BRET 
experiments were performed following the protocol described here. 
Applications of the Method 
Rluc-arrestin3-FlAsH constructs can be used to determine the amplitude 
and direction of change in net BRET (Δ net BRET) occurring between the Rluc 














Figure 3.1. Computer-generated 3D model of RLuc-arr3-FlAsH constructs. 
Three-dimensional model of beta-arrestin2 FlAsH BRET biosensors. Locations 
of the six C-C-P-G-C-C FlAsH acceptor sites are shown as yellow space-filling 
molecules. The FlAsH molecule is shown bound to the F1 site. The structure of 
the N-terminal Renilla luciferase is shown in blue. The position of the RLuc is 





protein. Using the full panel of reporters allows one to construct an arrestin3 
“conformational signature” that represents the effect of GPCR activation on the 
population average arrestin3 conformation. Work to date suggests that different 
ligand/GPCR complexes confer distinctive arrestin3 conformations, that features 
of these signatures are conserved between receptors with similar arrestin 
binding/signaling characteristics, and that the Δ Net BRET at selected positions 
correlates with arrestin’s downstream trafficking and signaling functions (Lee et al 
2016).   Potential applications of the method include functional 
classification/comparison of GPCRs and/or panels of ligands and identifying 
factors that influence arrestin conformation and ultimate function, e.g. ligand 
‘bias’ (Luttrell 2014), GPCR C-tail “phosphorylation codes” written by different 
GRKs (Tobin et al 2008), and post-translational modifications of arrestin that 
stabilize/destabilize the complex (Kommaddi 2013). 
The intramolecular FlAsH-BRET technique is likewise adaptable to many 
other allosterically regulated proteins, including GPCRs (Devost et al 2017). 
Single acceptor-site reporters can be used to detect whether the target protein 
undergoes a conformational shift in response to a stimulus, while placing the 
acceptor at multiple locations may discern different “patterns” of activation 
induced by different stimuli. The principles discussed above would apply when 
designing any FlAsH-BRET biosensors, with the added consideration that for 
transmembrane proteins, e.g. GPCRs, the Rluc donor and tetracysteine motifs 
must be on the same side of the plasma membrane, e.g. intracellular or 
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extracellular, for BRET to occur.   
Comparison with Other Methods 
Intramolecular BRET employing an Rluc-arrestin2-YFP construct has 
been used to monitor the conformational rearrangement in arrestin occurring 
upon GPCR binding and determine its kinetics (Zhan et al 2011).  Using this 
approach, at 25 ˚C the half time of maximal intramolecular BRET increase (τ½) 
following arrestin3 binding to the V2 vasopressin receptor (V2R) was around 5 
min, compared to <1 min for the τ½ increase in intermolecular BRET between 
Rluc-arrestin3 and a V2R-YFP pair, suggesting that the conformational 
rearrangement in arrestin3 occurs more slowly than arrestin binding.  The 
approach has also been used to compare the effects of different ligands on the 
angiotensin AT1A receptor (AT1AR) and type 1 parathyroid hormone receptor 
(PTH1R), where it was found that while conventional ligands caused an increase 
in net BRET between the N- and C-terminal donor-acceptor pair, arrestin-
selective “biased” ligands produced small shifts in the opposite direction, 
suggesting that ligand structure can influence arrestin conformation (Shukla et al 
2008).   
 Stimulus-induced arrestin3 conformational shifts have also been examined 
using intramolecular FlAsH-flourescence resonance energy transfer (FRET), 
which uses an N-terminal cyan fluorescent protein (CFP) donor and internal 
FlAsH acceptors (Nuber et al 2016). This approach also documents the 
existence of GPCR-specific patterns of arrestin activation. Its advantages over 
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Rluc-arrestin3-FlAsH BRET include superior temporal resolution, e.g. recruitment 
to a pre-stimulated β2 adrenergic receptor (β2AR) at 37 ˚C occurs with a τ½ of 
only 1.2 sec followed by a conformational change occurring with τ½ of 2.2 sec.  
Since FRET is generally measured using dual photon fluorescence microscopy 
at the single cell level, a disadvantage of this approach is the challenge of 
relating arrestin3 FlAsH-FRET profiles to its downstream functions, e.g. receptor 















Human embryonic kidney 293 (HEK293) cells were used. Cells were 
grown in growth medium consisting of minimum essential medium (MEM) 
containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 
antibiotic/antimycotic. HEK293 cells were maintained in 10 cm2 plastic cell culture 
dishes and grown in an incubator maintained at 37º C and 5% CO2. Cells were 
passaged at 90% confluency. HEK293 cells were used for experiments on 
passages two through eight (P2-P8). 
Arrestin3-FlAsH-BRET constructs  
The pcDNA3.1 plasmid encoding rat arrestin3 tagged at the N-terminus 
with Renilla luciferase (rLuc) was a gift from M. Bouvier (University of Montreal, 
Montreal, Quebec, Canada). A series of six rLuc-arrestin3-FlAsH BRET reporters 
were constructed by inserting a cDNA sequence encoding the amino acid motif, 
C-C-P-G-C-C, immediately following amino acid residues 40, 140, 171, 225, 263, 
and 410 of arrestin3, using a modification of the precise gene fusion PCR 
method of Yon and Fried (1989). For each construct, two PCR steps were 
performed using the primer sets shown in Table 3.1. The first step was to 
generate two PCR fragments using the primer pairs: RlucHindF/FlashR and 
FlashF/RlucApalR. One PCR product contained a HindIII restriction site at the 5’ 























TABLE 3.1. Primer sequences used to generate Rluc-arrestin3-FlAsH1-6   
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complementary FlAsH sequence at the 5’ end and an ApaI restriction site at the 
3’end. A second PCR step was used to fuse the two fragments using three 
primers: RlucHindF, FlashR and RluApalR, and the two PCR fragments as 
template DNA. The resultant full-length arrestin3 PCR product containing the 
FlAsH motif insert was digested with HindIII and ApaI and cloned into the parent 
rLuc-arrestin3 plasmid to generate the rLuc-arrestin3-FlAsH1–6 expression 
plasmids. All constructs were verified by dideoxynucleotde sequencing. 
FlAsH BRET protocol	
      HEK 293 cells were culture and maintained in 10 cm plastic tissue culture 
dishes. Cells were grown in MEM containing 10% FBS and 
antibiotic/antimycotic.  On day one, when cells reached approximately 90% 
confluency, they were split to 6-well plastic tissue culture plates. Cells were split 
at a density such that they would be ready to be transfected the following day.  
   On day 2, cells were transfected.  At this point, they were at 
approximately 50% confluency in the 6-well plates. For each transfection, 94 µL 
of MEM and 6 µL of FuGENE HD was combined in a microfuge tube, vortexed 
to mix, and pulsed in a centrifuge. Transfection reaction was incubated for five 
minutes. To each transfection reaction, 1.2 µg of untagged receptor plasmid 
DNA and 150 ng β-arrestin2 FlAsH reporter construct plasmid DNA were 
added. Tubes were gently inverted several times to mix and pulsed in the 
centrifuge. Each reaction was incubated for 5 minutes. Transfection reactions 
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were added to cells and return cells to incubator. 
      On day 3, media was aspirated from cells and discarded. Media was 
replaced with 2 mL of MEM containing 10% FBS and antibiotic/antimycotic. 
      On day 4, the experiment was performed.  Details of specific 
experiments varied and are described below.  The general format of the 
FlAsH-BRET experiments are as follows. 
      Media was aspirated from cells and discarded. Cells were detached 
by adding 1 mL of PBS containing 2 mM EDTA to each well.  Cells were 
pipetted and transfered to 1.5 mL microfuge tubes. Tubes were centrifuged 
at 3,000 x g for 3 minutes. Supernatant was aspirated and discarded.  
Cells were resuspended in 500 µL of Hanks’ Balanced Salt Solution 
(HBSS). Cells were pipetted several times to disperse cells. To each tube, 
0.67 µL of FlAsH-EDT2 was added. Tubes were gently inverted four to five 
times to mix and incubated at room temperature in the dark for 30 minutes.  
Following the incubation period, tubes were centrifuged at 3,000 x g for 3 
minutes. Supernatant was aspirated and discarded. Cells were 
resuspended in 1 mL 1 X BAL wash buffer from the FlAsH EDT2 reagent 
kit. Tubes were centrifuged at 3,000 x g for 3 minutes. Supernatant was 
aspirated and discarded. Cells were resuspended in 650 µL of BRET 
buffer.  Cells were mixed by pipetting several times to ensure cells were 
evenly dispersed. 
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      One hundred µL of cell suspension was transferred to each well of 
an opaque white 96-well plate. After completing transfer of cells to the 96-
well experimental plate, plates were wrapped in aluminum foil until ready 
to perform the experiment.  
      To prepare the drug plates, drugs were diluted to 12X desired final 
concentration in BRET buffer.  For each experimental well, approximately 15 µL 
of drug was aliquoted in multichannel pipette microfuge tubes or a 96-well drug 
plate. 
      RLuc-arr3- FlAsH cDNA expression was verified by measuring YFP 
fluorescent with an excitation wavelength of 515 nM and emission wavelength 
of 525 nM. After confirmation of construct expression by YFP fluorescence, 10 
µL of drug or vehicle consisting of BRET buffer were added to each well using a 
multichannel micropipettor. Drug mixing was ensured by pipetting up and down 
gently several times. Immediately after adding drug to the assay plate, 
coelenterazine was prepared by adding 25 µL of stock solution to 1 mL of BRET 
buffer. After thorough vortexing, 10 µL of diluted coelenterazine was added to 
each well. The assay plate was put in a Berthold Tristar 3 LB 941 Multi-mode 
Microplate Reader and emission at the wavelength ranges of 458 nm and 530 
nm were measured for coelenterazine luminescence and YFP respectively. The 
BRET ratio was measured as the luciferase value divided by the YFP value. 
Changes in BRET were measured as the difference of the vehicle-treated 
control and the drug-stimulated values. Analysis of data was performed in 
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GraphPad Prism. 
Time course experiments 
Cells transfected with plasmid cDNA encoding the bradykinin B2 receptor (B2R) 
and β-arrestin2 FlAsH-BRET reporters were prepared for BRET as described 
above. Cells were treated with 1 µM bradykinin at either time zero, two minutes, 
four minutes, six minutes, or eight minutes representing the time points for two, 
four, six, eight, and ten minutes respectively. Following addition of bradykinin at 
the last time point, coelenterazine was added and the plate was read using 
specifications indicated above. 
Dose-response curve generation 
Cells were prepared for BRET as described above. Cells were treated with 
bradykinin doses that ranged from 1 nm to 3 µM in half-log intervals. The plate 
was read using the specifications indicated above. 
Determining the effect of receptor density 
Cells were prepared for BRET as described above, with only the 
transfection protocol altered. All cells were transfected with 150 ng of RLuc-arr3-
F4 cDNA. Cells were also co-transfected with the concentration of BK2R plasmid 
cDNA indicated, ranging from 100 ng to 1.5 µg. Each transfection reaction also 
contained empty vector plasmid cDNA to bring the total transfection mass for 
each reaction to 1.65 µg. During the BRET experiment, all conditions were 
treated with either vehicle or 1 µM bradykinin. Otherwise, no modifications were 
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made to the general FlAsH BRET protocol. 
Determining the effect of biosensor expression level 
Cells were prepared for BRET as described above, with only the 
transfection protocol altered. All cells were transfected with 1.2 µg of B2R plasmid 
cDNA. Cells were also co-transfected with the concentration of RLuc-arr3-F4 
cDNA indicated, ranging from 10 ng to 500 ng.  Each transfection reaction also 
contained empty vector plasmid cDNA to bring the total transfection mass for 
each reaction to 1.7 µg. During the BRET experiment, all conditions were treated 
with either vehicle or 1 µM bradykinin. Otherwise, no modifications were made to 
the general FlAsH BRET protocol. 
Determining the effect of assay temperature 
Cells were transfected with 1.2 µg of B2R and 150 ng of RLuc-arr3-FlAsH 
per the transfection protocol above and prepared for BRET as described above. 
For the group incubated at room temperature, no modifications were made to the 
BRET protocol. For the group incubated at 37ºC, following addition of bradykinin, 
cells were placed in a tissue culture incubator for ten minutes prior to addition of 
coelenterazine.  For both groups, drug stimulation conditions were 1 µM 





The β-arrestin2 FlAsH BRET biosensor signal is stable over time 
  HEK293 cells were transfected with angiotensin AT1A receptor and 
prepared for the BRET experiment as described above.  For each experimental 
replicate, the same transfection reaction was used for each time point, and cells 
were pooled to remove variations in transfection efficiency from influencing 
changes in signal intensity.  For all three beta-arrestin 2 FlAsH BRET 
conformational profiles examined, a significant change in NET BRET was 
observed at the earliest time point (two minutes of drug stimulation) compared to 
the zero time point.  This change in NET BRET was stable across all time points 
examined, out to ten minutes of drug stimulation prior to addition of 
coelenterazine and plate reading, and did not significantly change compared to 
the reading made at the two minute time point. These findings are shown in 
Figure 3.2. 
The F5 beta-arrestin2 intramolecular FlAsH BRET biosensor exhibits 
normal dose-response 
 HEK293 cells were transfected with BK2R and F5 beta-arrestin 2 FlAsH 
BRET biosensor plasmid cDNA and prepared for the BRET assay as described 
above. Cells were stimulated with bradykinin for two minutes with concentrations 
ranging from 1 nM to 3 µM using half-log intervals.  A standard dose-response 















Figure 3.2. Change in BRET is stable throughout a ten minute time course for 
RLuc-arr3- FlAsH conformational biosensors. The change in BRET was 
observed at five time points after addition of 1 µM Ang II to cells transfected 
with AT1AR and one of RLuc-arr3-F4, -F5, or -F6 constructs. For each of the 
three constructs examined, the magnitude of the change in BRET was 
essentially maximal at the earliest time point and remained stable throughout 
the course of the experiment. Each experiment was performed in triplicate, n 
= 4 independent experiments, and # represents p < 0.05 relative to 0 as 

















Figure 3.3. Dose-dependence of RLuc-arr3-F5 signal in response to bradykinin 
stimulation. The change in intramolecular BRET of the RLuc-arr3-F5 arrestin 
conformational biosensor was measured in response to concentrations of 
bradykinin ranging from 1 nM to 3 µM in half-log intervals. A dose-response 
relationship with an EC50 of 33 nM and a Vmax of a change in NET BRET of -
0.022 was observed. Each experiment was performed in triplicate, n = 4 




NET BRET of -0.24 and a Km of 3.1 x 10-7 M were observed. 
The F5 β-arrestin2 intramolecular FlAsH BRET biosensor is affected by 
receptor density 
 HEK293 cells were transfected with a constant amount of F5 beta-arrestin 
2 FlAsH BRET biosensor plasmid cDNA and a varying amount of B2R plasmid 
cDNA and prepared for BRET assays as described above. The amount of B2R 
plasmid cDNA was varied from 100 ng, 300 ng, 500 ng, 750 ng, 1.2 µg, and 1.5 
µg to induce expression of varying receptor density.  Increasing receptor density 
up to 750 ng of B2R cDNA increased the amplitude of the change in BRET 
occurring upon stimulation.  A change in NET BRET of -0.17 was observed when 
transfecting 750 ng of B2R plasmid cDNA and transfection of additional BK2R 
plasmid cDNA did not significantly increase the signal intensity observed (Figure 
3.4). 
The F5 β-arrestin2 intramolecular FlAsH BRET biosensor signal intensity is 
maximized at intermediate expression levels 
 HEK293 cells were transfected with a constant amount of BK2R plasmid 
cDNA and a variable amount of F5 beta-arrestin 2 FlAsH BRET biosensor 
plasmid cDNA and prepared for BRET assays as described above.  The 
biosensor was transfected in amounts of 10, 50, 100, 300, 500, and 800 ng in 
order to determine transfection conditions optimal for observation of changes in 
















Figure 3.4. RLuc-arr3-F5 BRET in response to varying BK2R receptor density. 
Cells were transfected with BK2R plasmid cDNA in amounts ranging from 100 ng 
to 1.5 µg and stimulated for two minutes with 1 µM bradykinin. The change in the 
NET BRET observed from the RLuc- arr3-F5 intramolecular BRET beta-arrestin 
2 conformational biosensor was measured.  Increasing the transfection amount 
increased the magnitude of the signal observed up to approximately 750 ng 
transfected, at which point the observed values leveled off. Each experiment was 


















Figure 3.5. Impact of transfecting varying amounts of RLuc-arr3-F5 on 
signal intensity.  RLuc-arr3-F5 was transfected in amounts of 10 ng, 50 
ng, 100 ng, 300 ng, 500 ng, or 800 ng with 1 µg of BK2R plasmid cDNA. 
The change in NET BRET was observed in response to treatment with 1 
µM bradykinin for two minutes. Values are represented as the mean +/- 
SEM. The change of the greatest magnitude was observed for the 10 ng 
transfection however these conditions showed considerable variability. 
Consistent and robust changes were observed in the 50 ng and 100 ng 
transfection conditions. All experiments were run in triplicate and n = 4 
independent experiments.  Error bars represent Mean +/- SEM. 
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transfection masses of the biosensor cDNA elicited more pronounced downward 
shifts in the changes in BRET ratio intensity.  In fact, the lowest transfection 
condition of 10 ng of biosensor produced the largest change, however high 
variability in the change observed make that condition more unreliable. Optimal 
transfection conditions for the biosensor were at 50 and 100 ng of biosensor. 
Temperature does not influence the β-arrestin2 intramolecular FlAsH BRET 
conformational profile 
Using the full panel of β-arrestin2 intramolecular FlAsH BRET biosensors 
enables the generation of a “conformational profile” that measures the change in 
BRET between the Rluc photon donor on the β-arrestin2 N-terminus and a FlAsH 
acceptor located at different points along the protein.  A representative F1-F6 
signature obtained using the B2R is shown in Figure 3.6. 
Full β-arrestin2 intramolecular FlAsH BRET conformational profiles were 
obtained for four Class B GPCR receptors and results for assays run at either 
room temperature or incubated at 37 ˚C were compared, as shown in Figure 3.7.  
GPCRs used for this experiment were type 1A angiotensin II (AT1AR), the 
parathyroid hormone type 1 receptor (PTH1R), the V2 vasopressin receptor 
(V2R), and the B2R. Confocal microscopy shows that incubating cells at 37 ˚C 
during drug stimulation results in trafficking fluorescent-tagged beta-arrestin 2 
into endosomal vesicles compared to aggregating on the plasma membrane in 

















Figure 3.6. Complete RLuc-arr3-FlAsH profile in response to bradykinin 
stimulation of the B2R.  The NET BRET was measured for cells co-transfected 
with B2R plasmid cDNA and one of the RLuc-arr3-FlAsH conformational 
probes and treated for two minutes with 1 µM bradykinin. Each experiment was 
completed in triplicate, n = 4 independent experiments, and * represents p < 
















Figure 3.7.  Impact of temperature on trafficking and RLuc-arr3-FlAsH 
conformational profiles for Class B GPCRs. RLuc-arr3-FlAsH profiling and 
confocal microscopy studies were performed with ten minute drug incubations 
at room temperature and at 37 ˚C. Confocal microscopy studies examined arr3-
GFP in response to stimulation of the AT1AR, PTH1R, B2R, and V2R and it was 
observed in all systems tested that incubation at 37 ˚C resulted in trafficking of 
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arrestin3 to endosomal vesicles while incubation at room temperature resulted 
in arrestin3 accumulation at the plasma membrane. Incubation temperature had 
no impact on RLuc-arr3- FlAsH profiles however.  Confocal images are 
representative of three separate experiments.  Each BRET experiment was 
performed in triplicate, n = 4 independent experiments, and * represents p < 
0.05 compared to 0 as determined by Student’s t-test. 
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trafficking observed at different temperatures by microscopy, the conformational 
profiles observed at different temperatures showed no influence of temperature 
on the changes in NET BRET observed in any receptor system or for any beta-
arrestin 2 conformational probe. This finding indicates that the conformational 
change that occurs in response to beta-arrestin 2 binding an activated GPCR is 
the direct result of engagement of the receptor and/or other binding partners, and 














In this chapter, we demonstrated β-arrestin 2 conformational profiling by 
RLuc-arr3-FlAsH intramolecular BRET biosensors.  The BRET signals were 
shown to exhibit measurable changes that were not influenced by the 
temperature at which the experiment was conducted, and were stable across a 
time course of at least ten minutes. Together these observations demonstrate the 
robustness of the assay and suggest that it could be scalable in a more high-
throughput setting. The signals also demonstrated a dose-response relationship 
to varying concentrations of drug stimulation, indicating that the assay is 
sensitive to the stimulation conditions and specific for detection of changes 
through the activation of the receptor in question. 
The results obtained in the two experiments where transfection conditions 
were manipulated are in line with assumptions made about both RET 
experiments and the nature of arrestin. When the amount of RLuc-arr3-FlAsH 
cDNA transfected was altered, there was essentially a direct relationship 
between transfecting less cDNA and observing BRET changes of greater 
magnitude. While this may seem counterintuitive at the outset, it is actually the 
expected result. Observed changes in BRET reflect a change in the population 
average of the status of the transfected biosensor molecules. In the absence of 
stimulation, arrestin (including the exogenous RLuc-arr3-FlAsH) is in the 
cytoplasm. Once the receptor is stimulated, a portion of the cytoplasmic arrestin 
pool is recruited to receptors and undergoes the characteristic conformational 
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shift, and in the case of recruited RLuc-arr3-FlAsH change the efficiency by 
which resonance energy transfer occurs.  In this case, receptor density is the 
limiting factor to arrestin recruitment. As RLuc-arr3-FlAsH abundance is 
increased, the amount of arrestin being recruited to activated receptors is not 
significantly changing, while the portion remaining in the cytoplasm increases. 
Thus, a relatively smaller portion of the population is being recruited to receptors 
and undergoing the changes requisite for change in the amount of resonance 
energy transfer occurring. Increasing the amount of BK2R cDNA transfected 
increased the observed changes in BRET for a similar reason. As more receptor 
becomes available to recruit cytoplasmic arrestin, a greater portion of the arrestin 
is being recruited. Eventually, however, essentially all of the transfected RLuc-
arr3-FlAsH is being recruited, and additional BK2R cDNA will have no additional 
effect. 
The lack of effect of temperature on beta-arrestin 2 conformational profiles 
lends insight to the conformational profile assay and to the nature of arrestin 
itself. The experiment was based on the observation that temperature has a 
distinct effect on the trafficking of GPCR-arrestin complexes as observed by 
fluorescent confocal microscopy. When cells are incubated at 37 ºC during drug 
stimulation, Class B GPCRs traffic to endosomal puncta.  However, if the same 
cells stimulated with the same drug are left at room temperature during the 
incubation period, receptor and arrestin will be retained at the plasma membrane. 
The mechanism for this observation is not fully understood, but it is possible that 
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there is insufficient activation energy present at room temperature for recruitment 
and activation of the endocytotic machinery. 
With this in mind, we were able to test whether or not subcellular 
localization had an influence on the conformation of beta-arrestin 2. With the 
conformational profiles showing no difference after incubation at 37 ºC compared 
to room temperature, it was clear that subcellular localization was in fact not 
influencing the conformation. A corollary to that observation is that the 
conformational shift that beta-arrestin 2 undergoes when binding a Class B 











FACTORS DETERMINING ARRESTIN CONFORMATION AND FUNCTION
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INTRODUCTION 
The formation of complexes between G protein-coupled receptors 
(GPCRs) and β-arrestins following receptor activation is a critical step in arrestin 
exerting its functions in GPCR desensitization and trafficking and heterotrimeric 
G protein-independent signaling. This was demonstrated in Chapter 2, where it 
was shown that β-arrestin 2-mediated signaling was unamplified downstream of 
type 1 parathyroid hormone receptor (PTH1R) activation. A corollary to this 
finding is that interaction with an activated receptor is requisite for β-arrestin 2 to 
be active. 
Modulation of GPCR/arrestin complex stability can be observed at 
a number of levels. In this chapter, we examined three such levels: GPCR 
subtype, post-translational modification of arrestin, and ligand structure. 
G protein-coupled receptor subtype 
As discussed previously, GPCR subtypes can generally be grouped into 
two classes based on the nature of the GPCR/beta-arrestin interaction induced 
by receptor stimulation (Oakley et al 2000). Class A GPCRs, exhibit a transient 
interaction with arrestin, with arrestin dissociating shortly after receptor 
internalization. As a result, in confocal microscopy studies with fluorescently 
tagged β-arrestin2, β-arrestin2 is visualized at the plasma membrane due to 
constant recycling to activated cell surface receptors. Class B GPCRs, induce a 
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more stable GPCR/β-arrestin interaction, with β-arrestin2 remaining in complex 
with internalized receptors for several minutes (even hours) in endosomal 
vesicles. In similar studies with fluorescently tagged β-arrestin2, β-arrestin 2 is 
seen in endosomes. These differences can be seen in Figure 4.1. 
Ubiquitination: an example of arrestin post-translational modification 
Ubiquitination is a reversible protein post-translational modification in 
which ubiquitin – an 8.5 kD protein moiety – is covalently attached to lysine 
residues on the substrate protein.  Ubiquitination occurs via a stepwise cascade 
in which three enzymes are involved: a ubiquitin-activating enzyme (E1), a 
ubiquitin-conjugating enzyme (E2), and a ubiquitin ligase (E3).  Tight regulation 
of protein ubiquitination is at least partially achieved by expression of a wide 
variety of ubiquitin cascade enzyme isoforms, especially at the level of E3 
enzymes, of which there are hundreds.  Protein ubiquitination occurs in one of 
two general forms: monoubiquitination and polyubiquitination. In 
monoubiquitination, a single ubiquitin moiety is covalently attached to substrate 
lysine and generally serves to regulate a signaling event or stability of a protein-
protein interaction. Monoubiquitination can occur at multiple sites within a single 
substrate protein. In polyubiquitination, following the attachment of a single 
ubiquitin moiety to the target substrate protein as seen in monoubiquitination, 
ubiquitin molecules are appended sequentially to lysines of other protein-bound 
















Figure 4.1. RLuc-arr3-F4 shift correlates with arr3 trafficking pattern. Class B 
GPCRs PTH1R and AT1AR demonstrate trafficking of arr3 to endosomal 
vesicles by confocal microscopy and show a characteristic downward shift in the 
RLuc-arr3-F4 conformational probe. Class A GPCRs alpha1BR, beta2AR, 
S1P1R, and alpha2AAR, however, do not show stable trafficking of arr3 to 
endosomes and do not exhibit the characteristic shift in the BRET value for 
RLuc-arr3-F4. From Lee et al (2016). 
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this type of polyubiquitination typically results in proteosomal degradation of the 
substrate protein.  Polyubiquitination can also occur through linkages at lysine 
63, which tends to serve in regulation of signaling and trafficking (Hicke 2001). 
β-Arrestins 1 and 2 are reversibly monoubiquitinated following GPCR 
activation. The role of ubiquitination was first observed when it was shown that 
blockade of E3 ubiquitin ligase Mdm2 impaired arrestin-mediated endocytosis of 
beta2-adrenergic receptors following their activation (Shenoy et al 2001). 
Subsequently, it was observed that Class B GPCRs also induce beta-arrestin 2 
ubiquitination resulting in increased GPCR/β-arrestin2 complex stability. 
Stimulation of the type 1A angiotensin II receptor (AT1AR), V2 vasopressin 
receptor (V2R), and neurokinin 1 receptor (NK1R) were all shown to induce β-
arrestin2 ubiquitination. The sites of ubiquitination, however, varied from 
receptor to receptor. Mutation of lysines 11 and 12 of β-arrestin 2 were shown to 
impair stable GPCR/β-arrestin 2 complex formation downstream of AT1AR 
stimulation by angiotensin II, but not downstream of V2R stimulation by 
vasopressin.  Conversely, mutation of lysines 18, 107, 108, 207, and 296 had 
the opposite effect, interrupting V2R signaling but not AT1AR. β-Arrestin 2 
mutations that prevent necessary receptor-specific ubiquitination events are also 
observed to have reduced β-arrestin 2-mediated ERK1/2 activation (Shenoy 
2007; Shenoy and Lefkowitz 2003; Shenoy and Lefkowitz 2005). 
Biased agonism of AT1AR 
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It has been frequently demonstrated that heterotrimeric G protein- 
dependent and –independent effects can be dissociated by structurally 
diverse ligands acting through a single receptor (Kenakin and Miller, 2010). 
Ligands that are able to activate – either partially or completely – certain 
subsets of a receptor’s typical signaling repertoire are referred to as ‘biased’ 
or ‘functionally selective.’ Biased ligands have been discovered and/or 
synthesized in a number of receptor systems. One of the most commonly 
studied systems for biased agonism is the AT1AR system. Amino acid 
substitutions in various combinations of the first, fourth, fifth, and eighth 
position of the endogenous octapeptide ligand, Ang II, have been shown to 
bias the receptor toward beta-arrestin 2-mediated effects while limiting, 
relatively, heterotrimeric G protein activation (Godin and Ferguson 2012). 
A 2012 study by Zimmerman et al examined a panel of five structural 
variants of Ang II known to exhibit varying degrees of bias. As part of their 
characterization of the ligands, they quantified the avidity of complexes formed 
between AT1AR and beta-arrestin 2 by fluorescence recovery after 
photobleaching (FRAP). Ligands exhibited a distinct rank-order in terms of 
complex avidity as measured by FRAP, and this complex avidity showed strong 
correlation with beta-arrestin 2-mediated ERK activation. 
Complex stability as determined by receptor subtype is reflected in 
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rLuc-arr3-FlAsH conformational profile 
As detailed in Chapter 3, our group developed a panel of rLuc-arr3-FlAsH 
conformational biosensor to examine conformational changes in β-arrestin 2 in 
response to varying stimuli.  The initial comparison made was between Class A 
and Class B GPCRs. As shown in Figure 4.1, we observed a conserved change 
in conformational profile in stable-binding Class B receptors that was not 
observed in transient-binding Class A receptors. Specifically, the F5 rLuc-arr3- 
FlAsH biosensor exhibited a significant downshift in all receptor systems where 
stable GPCR/beta-arrestin 2 complex formation was observed, and no 
significant change in receptor systems where stable complex formation was not 
observed (Lee at al 2016). 
Hypothesis 
We hypothesized that, in addition to Class A versus Class B receptor 
subtype, other factors such as β-arrestin 2 post-translational modification and 
ligand structure that influence GPCR/β-arrestin 2 complex avidity will also be 
reflected in rLuc-arr3-FlAsH conformational profiles. To test this hypothesis, we 
examined rLuc-arr3-FlAsH conformational profiles in ubiquitin-insensitive 






Cells were grown in growth medium consisting of minimum essential 
medium (MEM) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 
and antibiotic/antimycotic. HEK293 cells were maintained in 10 cm2 plastic cell 
culture dishes and grown in an incubator maintained at 37º C and 5% CO2. 
Cells were passaged at 90% confluency. HEK293 cells were used for 
experiments on passages two through eight (P2-P8). 
FlAsH BRET protocol 
HEK 293 cells were maintained in 10 cm plastic tissue culture dishes. 
Cells were grown in MEM containing 10% FBS and antibiotic/antimycotic.  On 
day one, when cells reached approximately 90% confluency, they were split to 
6-well plastic tissue culture plates. Cells were split at a density such that they 
would be ready to be transfected the following day.  
On day 2, cells were transfected.  At this point, they were at 
approximately 50% confluency in the 6-well plates. For each transfection, 94 µL 
of MEM and 6 µL of FuGENE HD was combined in a microfuge tube, vortexed 
to mix, and pulsed in a centrifuge. Transfection reaction was incubated for five 
minutes. To each transfection reaction, 1.2 µg of untagged receptor plasmid 
DNA and 150 ng β-arrestin2 FlAsH reporter construct plasmid DNA were 
added. Tubes were gently inverted several times to mix and pulsed in the 
centrifuge. Each reaction was incubated for 5 minutes. Transfection reactions 
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were added to cells and return cells to incubator. 
      On day 3, media was aspirated from cells and discarded. Media was 
replaced with 2 mL of MEM containing 10% FBS and antibiotic/antimycotic. 
      On day 4, the experiment was performed.  Details of specific 
experiments varied and are described in the results section.  The general 
format of the FlAsH-BRET experiments are as follows. 
      Media was aspirated from cells and discarded. Cells were 
detached by adding 1 mL of PBS containing 2 mM EDTA to each well.  
Cells were pipetted and transfered to 1.5 mL microfuge tubes. Tubes were 
centrifuged at 3,000 x g for 3 minutes. Supernatant was aspirated and 
discarded.  Cells were resuspended in 500 µL of Hanks’ Balanced Salt 
Solution (HBSS). Cells were pipetted several times to disperse cells. To 
each tube, 0.67 µL of FlAsH-EDT2 was added. Tubes were gently inverted 
four to five times to mix and incubated at room temperature in the dark for 
30 minutes.  Following the incubation period, tubes were centrifuged at 
3,000 x g for 3 minutes. Supernatant was aspirated and discarded. Cells 
were resuspended in 1 mL 1 X BAL wash buffer. Tubes were centrifuged 
at 3,000 x g for 3 minutes. Supernatant was aspirated and discarded. Cells 
were resuspended in 650 µL of BRET buffer.  Cells were mixed by 
pipetting several times to ensure cells were evenly dispersed.  100 µL of 
cell suspension was transferred to each well of the opaque, white 96-well 
plate. After completing transfer of cells to the 96-well experimental plate, 
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plates were wrapped in aluminum foil until ready to perform the 
experiment.  
      To prepare the drug plates, drugs were diluted to 12X desired final 
concentration in BRET buffer.  For each experimental well, approximately 15 µL 
of drug was aliquoted in multichannel pipette microfuge tubes or a 96-well drug 
plate. 
      RLuc-arr3- FlAsH cDNA expression was verified by measuring YFP 
fluorescent with an excitation wavelength of 515 nM and emission wavelength 
of 525 nM. After confirmation of construct expression by YFP fluorescence, 10 
µL of drug or vehicle consisting of BRET buffer were added to each well using a 
multichannel micropipettor. Drug mixing was ensured by pipetting up and down 
gently several times. Immediately after adding drug to the assay plate, 
coelenterazine was prepared by adding 25 µL of stock solution to 1 mL of BRET 
buffer. After thorough vortexing, 10 µL of diluted coelenterazine was added to 
each well. The assay plate was put in the instrument and absorbance at the 
wavelength ranges of 458 nm and 530 nm were measured for coelenterazine 
luminescence and YFP respectively. The BRET ratio was measured as the 
luciferase value divided by the YFP value. Changes in BRET were measured as 
the difference of the vehicle-treated control and the drug-stimulated values. 





K11/12R mutation of β-arrestin2 differentially impacts trafficking 
HEK293 were transfected to co-express either ubiquitin site-mutated or 
wild type YFP-tagged β-arrestin2 and one of four Class B GPCRs. The putative 
ubiquitin sites mutated were lysines 11 and 12. Lysines at these locations were 
replaced with arginines, which cannot be ubiquitinated.  Receptors used for this 
and subsequent studies were the type 1A angiotensin II receptor (AT1AR), the 
type 2 bradykinin receptor (BK2R), the type 1 parathyroid hormone receptor 
(PTH1R), and the V2 vasopressin receptor (V2R). The K11/12R mutation has 
been previously shown to disrupt stable GPCR/β-arrestin2 complex formation 
downstream of the AT1AR, resulting in confocal microscopy of fluorescently 
tagged β-arrestin2 bearing this mutation resembling a Class A receptor instead 
of a Class B receptor. Conversely, this mutation has been shown to have no 
effect on trafficking downstream of the V2R.  As shown in Figures 4.2 and 4.3, 
this same phenomenon was observed in our system. 
The impact of the K11/12R mutation on trafficking downstream of BK2R 
and PTH1R was previously unknown. As shown in Figure 4.2, the K11/12R 
mutation disrupted normal complex formation downstream of the BK2R, 
indicating that ubiquitination at these sites is necessary for stable complex 
formation in this receptor system. However, as shown in Figure 4.3, the K11/12R 
was observed to have no impact on trafficking downstream of PTH1R activation. 
















Figure 4.2. Systems that are sensitive to K11,12R ubiquitination site 
mutation as determined by trafficking also show differences in 
conformational signature.  Mutation of the ubiquitination sites lysine 11 
and 12 to arginine resulted in the loss of stable trafficking to endosomes 
as observed by confocal microscopy of cells transfected with GFP-tagged 
arr3 (with or without the ubiquitination site mutation) and either AT1AR or 
BK2R and stimulated with either 1 uM Ang II or 1 uM bradykinin 
respectively. Comparatively, mutation of lysines 11 and 12 in RLuc-arr3-
F4, -F5, and –F6 resulted in the loss of changes in NET BRET for both 
receptor/ligand systems.  Confocal images representative of three 
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independent experiments. Each BRET experiment was performed in 
triplicate, n = 5 independent experiments, and * represents p < 0.05 





















Figure 4.3. Systems that are insensitive to K11/12R ubiquitination site mutation 
of arrestin3 show no differences in conformational profiles.  Trafficking was 
examined by monitoring of GFP-tagged arr3 (with or without mutation to lysine 
11 and 12 ubiquitination sites) by confocal microscopy in cells transfected with 
V2R and stimulated with vasopressin and cells transfected with PTH1R and 
stimulated with PTH[1-34].  In both of these systems, trafficking was 
unaffected by the mutation. Similarly, mutation of lysines 11 and 12 in the 
RLuc-arr3-F4, - F5, and –F6 probes had no impact on the conformational 
profiles obtained. Confocal images representative of three independent 
 93 
experiments. Each BRET experiment was performed in triplicate, n = 5 
independent experiments, and * represents p < 0.05 compared to 0 as 







these lysines in this model, it suggests that at the very least, this event is not 
necessary and sufficient to produce stable GPCR/β-arrestin 2 complex 
formation. 
K11/12R mutation of rLuc-arr3-FlAsH biosensors causes 
conformational signature changes that reflect trafficking 
Lysines 11 and 12 were mutated to ubiquitination-deficient arginines for 
the F4, F5, and F6 rLuc-arr3-FlAsH conformational biosensors as described 
above. Abbreviated rLuc-arr3-FlAsH conformational profiles using the F4, F5, 
and F6 biosensors were performed in parallel with cells expressing either 
mutated and nonmutated constructs. Cells also expressed one of the AT1AR, 
B2R, PTH1R, or V2R receptor panel. Conformational profiles were determined for 
each system by stimulation with each receptor’s reference ligand: Ang II, 
bradykinin, PTH[1-34], and Arg-vasopressin, respectively. 
As expected based on previous studies, the profiles obtained using wild 
type rLuc-arr3-FlAsH constructs shared the common changes observed when 
activated by Class B receptors: F4 and F5 significantly decreased, and F6 
significantly increased. While the mutation caused slight decreases in the 
magnitude of shifts observed downstream of the two receptor systems that 
were insensitive to the K11/12R mutation in confocal microscopy studies (V2R 
and PTH1R), the differences compared to nonmutated were not significant, 
and displayed the same conserved pattern. Alternatively, the mutation 
markedly reduced the shifts observed for all three rLuc-arr3-FlAsH 
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conformational biosensors in the receptor systems that were impacted by the 
K11/12R mutation (AT1AR and B2R).  Consistent with the Class B to Class A 
shift in β-arrrestin2 binding observed by confocal microscopy when these 
receptors interact with K11/12R β-arrestin2 (Figure 4.2) the observed FlAsH-
BRET signatures for the AT1AR and B2R binding K11/12R β-arrestin2 resembled 
those seen when wild type β-arrestin2 binds the Class A β2 adrenergic 
receptor (β2AR) and α1B adrenergric receptor (α1BAR)  (Figure 4.1). 
Biased AT1AR ligands produce stable receptor/arrestin complexes 
HEK293 cells were transfected to co-express AT1AR and YFP-tagged β-
arrestin 2 as described above.  Cells were stimulated with either the reference 
ligand (Ang II) or one of four biased ligands (SI, SII, SBpA, SVdF). Cells were 
observed under confocal microscopy. As shown in Figure 4.4, all ligands were 
observed to induce a stable Class B pattern of AT1AR/beta-arrestin 2 complex 
formation as evidenced by the appearance of distinct cytoplasmic puncta. The 
appearance of cells stimulated by different ligands are essentially 
indistinguishable in the microscope. 
Complex avidity is correlated with F4 rLuc-arr3-FlAsH magnitude 
HEK293 cells were transfected to co-express AT1AR and one of the 
F1, F4, F5, or F6 rLuc-arr3-FlAsH conformational biosensors. Conformational 
signatures were obtained for Ang II and each of the biased ligands (SI, SII, 
SBpA, and SVdF) as shown in Figure 4.5. 

















Figure 4.4. AT1AR full and biased ligands all form stable receptor/arrestin 
complexes. HEK293 cells were transfected with arr3-GFP and AT1AR plasmid 
cDNA. Cells were treated with one of five AT1AR ligands (Ang II, SBpA, SVdF, 
SI, or SII) for ten minutes and arrestin trafficking was observed via confocal 
microscopy. As evidenced by the presence of distinct puncta, each ligand 
produced stable receptor/arrestin complexes. Confocal images are 



















Figure 4.5. RLuc-arr3-FlAsH profiles for AT1AR ligands. Each experiment was 
performed in triplicate, n = 6 independent experiments, and * represents p < 
0.05 as determined by Student’s t-test. 
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same for the reference ligand and all of the biased ligands. The directionality for the 
F6 shift, however, distinguished the full and biased ligands: Ang II caused an 
upward shift at F6, while the four biased ligands all produced a downward shift. The 
magnitude of the F1 shift showed no significant differences between any of the 
ligands, while the F4 and F5 shifts could each be partitioned into three distinct 
groups: for each, Ang II exhibited the shift with the largest magnitude, SI and SII 
exhibited the shifts with the smallest magnitude, and SBpA and SVdF produced 
intermediately sized shifts. 
As discussed previously, the F4-rLuc-arr3-FlAsH biosensor correlated 
with trafficking in experiments with different GPCR subtypes. In light of this, we 
compared the magnitude of the shifts observed at this position with the complex 
avidity as quantified by FRAP in Zimmerman et al.  We observed a strong linear 
correlation between the change in NET BRET and complex avidity.  Note that 
complex avidity for SII could not be quantified as the off-rate was too high to 





















Figure 4.6.  Magnitude of RLuc-arr3-F4 signal correlates with AT1AR-arr3 
complex avidity. The NET BRET value for each ligand using the RLuc-arr3-F4 
probe was compared to the complex avidity as determined by FRAP in 
Zimmerman et al.  The location of SII is estimated because complex avidity 
could not be quantified by FRAP. The relationship has an r2 value of 0.96.
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DISCUSSION 
This chapter establishes RLuc-arr3-FlAsH BRET conformational profiling 
as a reliable predictor of the stability of GPCR-arrestin complex formed under 
given system and stimulation conditions. Specifically, changes in BRET as 
observed by the RLuc-arr3-F4 biosensor directly correlated with complex 
avidity between activated GPCRs and β-arrestin2. 
Work that was performed outside of this dissertation and presented in 
Lee et al (2016) first showed the relationship by comparing conformational 
signatures generated in response to Class A and Class B GPCRs. The major 
defining characteristic that separates Class A and Class B GPCRs is the ability 
for arrestin to induce stable complex formation and traffic to endosomes when 
activated by Class B, but not Class A, GPCRs (Oakley et al 2000). The 
conformational profiles observed were consistent within a class, and wholly 
distinct when comparing one class to another. One of the specific differences 
between Class A and Class B GPCRs was the signal observed in the RLuc-
arr3-F4 biosensor; in response to activation of Class B receptors there was a 
conserved downward shift observed, and in response to activation of Class A 
receptors there was no significant shift observed. 
 The studies examining differences in ubiquitination patterns of β-arrestin2 
in response to different activating receptors presented a second example where 
there was an observable change in trafficking that was reflected in the observed 
conformational profile. Mutation of two ubiquitination sites on β-arrestin2 was 
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sufficient to make β-arrestin2 interact with two Class B GPCRs (AT1AR and B2R) 
as if they were Class A GPCRs. As expected, mutation of the same sites on the 
RLuc-arr3-FlAsH constructs likewise prevented the characteristic changes in 
BRET observed under these conditions. This observation strengthens the 
conclusions drawn from the receptor subtype studies because it shows 
alteration of the complex stability alone (and not something inherent about 
activation of Class B GPCRs) is encoded in the beta-arrestin 2 conformational 
signature. 
In the final study examining β-arrestin2 conformational profiles observed 
in response to stimulation of a single receptor with multiple ligands of varying 
efficacy, we demonstrated that changes in the RLuc-arr3-F4 signal can also 
detect subtle differences in complex avidity. While we observed that all of the 
ligands induced stable complex formation by confocal microscopy, previous 
work by Zimmerman et al demonstrated by FRAP that the complexes exhibited 
varying degrees of avidity. The RLuc-arr3-F4 signal showed a direct correlation 
with complex avidity as quantified by FRAP. The detection of subtle differences 
in complex avidity in comparison to the all-or-nothing examples provides the 
strongest evidence to date that functional information is encoded in the beta- 
arrestin 2 conformational signature. 
Future directions for this work include examining another level of 
regulation of complex avidity: post-translational modification of the receptor. 
Mounting evidence suggests that differential phosphorylation of GPCRs by 
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different GRK isoforms results in differences in arrestin functionality.  GRK2 and 
3 have been shown to favor complex formation and receptor desensitization, 
while GRK5 and 6 have been shown to promote arrestin-mediated signaling 
(Kim et al 2005; Noma et al 2007). Perturbation of GRK2 and 3 (by inhibitor 
and/or knockdown) could therefore promote altered GPCR-arrestin complex 
formation, and examining beta-arrestin 2 conformational profiles in these 
conditions could provide another level of support to the hypothesis that the 
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The present study set out to examine potential mechanisms for how 
arrestin integrates and interprets various input stimuli to determine its outcome 
function.  As discussed in previous chapters, arrestin function varies greatly 
based on the context in which it is activated. It has been long known that 
arrestin behaves differently in response to activation by different receptors: 
Class B GPCRs induce arrestin to promote stable trafficking of receptor-arrestin 
complexes to endosomes and a robust activation of arrestin-dependent 
signaling, while Class A GPCRs are removed from the plasma membrane by 
arrestin in the same fashion but are instead rapidly recycled to the plasma 
membrane and resensitized.  Subsequently it was determined that different 
ligands acting through the same receptor could induce arrestin activities of 
varying appearances. We hypothesized that arrestin function is dictated by the 
conformational change imprinted upon it both by interaction with the interface of 
an activated receptor and direct post-translational modifications. 
The primary findings of this work support the idea that arrestin 
functionality is dictated by discrete conformational changes induced upon 
binding activated GPCRs. In Chapter 2, it was established that arrestin-
mediated signaling events, in contrast to heterotrimeric G protein-mediated 
signaling events, are not amplified. The lack of amplification supports the 
requirement of arrestin being in complex with an activated receptor in order to 
exert is actions; the stoichiometric relationship between arrestin recruitment and 
arrestin-mediated signaling implies that signaling is only occurring in the 
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presence of arrestin in complex with activated receptors.  While Chapter 3 
focused on the introduction and optimization of the RLuc-arrestin3-FlAsH model 
of arrestin conformational profiling, the lack of impact of subcellular localization 
on arrestin conformational profiles further supports the notion that the key step 
in determining arrestin conformational shifts is the engagement of arrestin with 
an activated receptor. In other words, the conserved conformational shifts 
observed in response to activation by Class B GPCRs occurs in response to 
arrestin binding an activated receptor, and is not an artifact of arrestin trafficking 
to different locations within the cell where it could be exposed to a different 
subcellular milieu.  In Chapter 4, it was demonstrated that conserved changes in 
arrestin conformational profiles were observed in the face of differences in the 
activating receptor and ligand and in response to changes in ligand-induced 
arrestin post-translational modification. Taken together, these findings suggest 
that arrestin conformational changes are at a minimum reflective, and potentially 
sufficient to determine, the actions which arrestin performs, and that this 
conformational change is the result of sustained interaction with an activated 
GPCR. 
While the notion that receptor-arrestin interaction dictates arrestin 
function has long been hypothesized, this work represents the most direct 
evidence of support. As detailed in Chapter 1, extensive structural work 
examining conformational changes in activated arrestin have been performed by 
X-ray crystallography. These studies demonstrate conserved changes in 
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arrestin structure, but the technological limitations and static nature of X-ray 
crystallography prohibit direct examination of complete GPCR-arrestin 
complexes, let alone how the structure of these complexes may differ when 
induced by different ligands.  The similarity of our conformational profiles in 
response activation by Class B GPCRs supports the idea that conformational 
changes in arrestin upon binding to activated receptors are largely conserved. 
Nuber et al (2016) suggest in their work that arrestin may maintain some level of 
activation briefly following dissociation of the receptor-arrestin complex.  
Specifically, they found that the intramolecular FlAsH FRET signal in their beta-
arrestin 2 conformational probes decayed slower than the intermolecular signal 
between receptor and arrestin following removal of stimulating ligand. 
 The nature of resonance energy transfer studies is a limitation to the 
interpretation of this work. Changes in BRET represent a population average of 
all of the molecules of the reporter and not necessarily changes in any individual 
molecule. As such, it may be necessary to temper interpretations of 
conformational profiling. Furthermore, even if conformational profiles are 
reflective of changes in individual arrestin molecules, there are multiple potential 
interpretations for this finding. While the simplest explanation is a direct 
conformational rearrangement of arrestin induced by the receptor, it is also 
possible that another distinct arrestin binding partner is inducing the 
conformational rearrangement, or that an arrestin binding is simply sterically 
preventing resonant energy transfer from occurring. The conserved arrestin 
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conformational profile observed in response to activation Class B receptors 
would at a minimum serve as a predictive signature in receptor and ligand 
systems where the induced functions of arrestin remain unknown. 
While the above limitation of this work lessens direct study of arrestin 
conformational rearrangements, this work establishes the RLuc-arrestin3-FlAsH 
biosensors as a potential tool for drug screening. Biased GPCR ligands have 
been thought to be a potential therapeutic avenue for a number of conditions. 
Arrestin-biased ligands of the AT1AR have been identified as potential 
therapeutics due to the observation of the benefits of both blockade of the 
renin-angiotensin II-aldosterone signaling axis and cardioprotective effects of 
arrestin-mediated signaling in models of cardiac failure (Rajagopal et al 2006; 
Tarigopula et al 2015). Conversely, the negative side effects of current mu 
opioid agonist analgesics (including dependence and constipation) are thought 
to be mediated by arrestin-mediated signaling, so a G protein-based ligand may 
provide a more effective therapeutic option (Bohn et al 1999; Bohn et al 2000).  
Despite this, current drug screening platforms are ineffective at identifying 
biased ligands.  In fact, most biased ligands are developed through modification 
and testing endogenous ligands, which is inefficient at best. Arrestin 
conformational profiling represents a technique that is scalable and could serve 
as part of a high throughput screening protocol to identify drugs with specific 
impacts on arrestin functionality. 
While the present findings suggest that arrestin-mediated signals are not 
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amplified, future studies may determine that, at least in some systems, 
amplification may be observed. One such system for consideration is 
stimulation of PTH1R by the modified bovine analog bPTH[7-34].  In this system, 
bPTH[7-34] has yet to be shown to even recruit β-arrestin2 to the plasma 
membrane. Despite this, bPTH[7-34] has been repeatedly shown to be capable 
of inducing arrestin- dependent activation of ERK under the same conditions.  
Consideration of one of the findings by Nuber et al may provide insight to the 
underlying mechanism of these seemingly at odds observations. Nuber et al 
showed that conformational changes as observed by FlAsH FRET β-arrestin2 
biosensors persisted for up to five seconds following the dissociation of the 
beta2 adrenergic receptor/beta- arrestin 2 complex. It is therefore possible that 
bPTH[7-34] is inducing a recruitment of β-arrestin2 where transience of the 
interaction surpasses the sensitivity of current methods of observation of 
complex formation, but is still able to induce a somewhat persistent 
conformational shift to β-arrestin2 that enables it to function in signal 
transduction. The transience of this interaction could allow for a single activate 
PTH1R to activate multiple molecules of β-arrestin2, and therefore amplification 
of arrestin-mediated signals could be observed. Indeed, unpublished work by 
our group has shown that despite not inducing a measurable recruitment to the 
plasma membrane, bPTH[7-34] does induce characteristic RLuc-arr3-FlAsH 
conformational profile. 
The present studies both provide insight to the understanding of how 
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arrestin translates signals to determine its function and lay the groundwork 
for translating these technologies from studying systems with known 
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